WO2004035755A2 - Transporters and ion channels
- Google Patents
Transporters and ion channels
Download PDF
Info
Publication number
WO2004035755A2
WO2004035755A2
PCT/US2003/033087
US0333087W
WO2004035755A2
WO 2004035755 A2
WO2004035755 A2
WO 2004035755A2
US 0333087 W
US0333087 W
US 0333087W
WO 2004035755 A2
WO2004035755 A2
WO 2004035755A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polynucleotide
polypeptide
amino acid
sequence
Prior art date
2002-10-16
Application number
PCT/US2003/033087
Other languages
French (fr )
Other versions
WO2004035755A3
(en
Inventor
April J.A. Hafalia
Reena Khare
Preeti G. Lal
Henry Yue
Mariah R. Baughn
Michael B. Thornton
Dyung Aina M. Lu
Craig H. Ison
Shanya D. Becha
Li Ding
Bridget A. Warren
Soo Yeun Lee
Anita Swarnakar
Vicki S. Elliott
Thomas W. Richardson
Joseph P. Marquis
Jayalaxmi Ramkumar
Jagi Murage
Brigitte E. Raumann
Monique G. Yao
Yan Lu
Kimberly J. Gietzen
Yonghong G. Yang
Hsin-Ru Chang
Narinder K. Chawla
Uyen K. Tran
Sally Lee
Junming Yang
Ameena R. Gandhi
Catherine M. Tribouley
Jennifer L. Policky
Huijun Z. Ring
Ernestine A. Lee
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2002-10-16
Filing date
2003-10-16
Publication date
2004-04-29
2003-10-16
Application filed by Incyte Corporation
filed
Critical
Incyte Corporation
2003-10-16
Priority to AU2003279980A
priority
Critical
patent/AU2003279980A1/en
2004-04-29
Publication of WO2004035755A2
publication
Critical
patent/WO2004035755A2/en
2004-08-26
Publication of WO2004035755A3
publication
Critical
patent/WO2004035755A3/en
Links
102000004310
Ion Channels
Human genes
0.000
title
description
37
102000040430
polynucleotide
Human genes
0.000
claims
abstract
description
481
108091033319
polynucleotide
Proteins
0.000
claims
abstract
description
481
239000002157
polynucleotide
Substances
0.000
claims
abstract
description
481
238000000034
method
Methods
0.000
claims
abstract
description
192
230000014509
gene expression
Effects
0.000
claims
abstract
description
114
239000005557
antagonist
Substances
0.000
claims
abstract
description
18
239000000556
agonist
Substances
0.000
claims
abstract
description
17
108090000765
processed proteins & peptides
Proteins
0.000
claims
description
292
102000004196
processed proteins & peptides
Human genes
0.000
claims
description
281
229920001184
polypeptide
Polymers
0.000
claims
description
273
210000004027
cell
Anatomy
0.000
claims
description
176
125000003275
alpha amino acid group
Chemical group
0.000
claims
description
161
239000012634
fragment
Substances
0.000
claims
description
126
150000001875
compounds
Chemical class
0.000
claims
description
105
208000037265
diseases, disorders, signs and symptoms
Diseases
0.000
claims
description
76
150000007523
nucleic acids
Chemical class
0.000
claims
description
76
125000003729
nucleotide group
Chemical group
0.000
claims
description
71
239000002773
nucleotide
Substances
0.000
claims
description
69
239000000523
sample
Substances
0.000
claims
description
64
230000000694
effects
Effects
0.000
claims
description
59
239000000203
mixture
Substances
0.000
claims
description
56
102000039446
nucleic acids
Human genes
0.000
claims
description
53
108020004707
nucleic acids
Proteins
0.000
claims
description
53
230000027455
binding
Effects
0.000
claims
description
48
238000012360
testing method
Methods
0.000
claims
description
46
201000010099
disease
Diseases
0.000
claims
description
45
230000000295
complement effect
Effects
0.000
claims
description
44
238000009396
hybridization
Methods
0.000
claims
description
44
108091032973
(ribonucleotides)n+m
Proteins
0.000
claims
description
41
108091034117
Oligonucleotide
Proteins
0.000
claims
description
29
238000012216
screening
Methods
0.000
claims
description
26
238000004519
manufacturing process
Methods
0.000
claims
description
20
238000011282
treatment
Methods
0.000
claims
description
20
230000002163
immunogen
Effects
0.000
claims
description
19
239000000758
substrate
Substances
0.000
claims
description
18
241001465754
Metazoa
Species
0.000
claims
description
17
239000012472
biological sample
Substances
0.000
claims
description
15
238000002493
microarray
Methods
0.000
claims
description
14
230000003247
decreasing effect
Effects
0.000
claims
description
13
230000009870
specific binding
Effects
0.000
claims
description
13
230000015572
biosynthetic process
Effects
0.000
claims
description
11
230000008859
change
Effects
0.000
claims
description
11
239000000546
pharmaceutical excipient
Substances
0.000
claims
description
9
230000009261
transgenic effect
Effects
0.000
claims
description
8
239000007787
solid
Substances
0.000
claims
description
6
238000012408
PCR amplification
Methods
0.000
claims
description
5
108060003951
Immunoglobulin
Proteins
0.000
claims
description
4
102000001706
Immunoglobulin Fab Fragments
Human genes
0.000
claims
description
4
108010054477
Immunoglobulin Fab Fragments
Proteins
0.000
claims
description
4
210000004408
hybridoma
Anatomy
0.000
claims
description
4
102000018358
immunoglobulin
Human genes
0.000
claims
description
4
230000002018
overexpression
Effects
0.000
claims
description
4
230000005875
antibody response
Effects
0.000
claims
description
3
238000012258
culturing
Methods
0.000
claims
description
3
230000003053
immunization
Effects
0.000
claims
description
3
238000002372
labelling
Methods
0.000
claims
description
3
210000000628
antibody-producing cell
Anatomy
0.000
claims
2
231100000683
possible toxicity
Toxicity
0.000
claims
2
238000002405
diagnostic procedure
Methods
0.000
claims
1
241000282414
Homo sapiens
Species
0.000
abstract
description
40
239000013604
expression vector
Substances
0.000
abstract
description
22
230000001594
aberrant effect
Effects
0.000
abstract
1
XRCFXMGQEVUZFC-UHFFFAOYSA-N
anisindione
Chemical compound
C1=CC(OC)=CC=C1C1C(=O)C2=CC=CC=C2C1=O
XRCFXMGQEVUZFC-UHFFFAOYSA-N
0.000
abstract
1
229960002138
anisindione
Drugs
0.000
abstract
1
108090000623
proteins and genes
Proteins
0.000
description
154
102000004169
proteins and genes
Human genes
0.000
description
91
235000018102
proteins
Nutrition
0.000
description
84
108091006146
Channels
Proteins
0.000
description
83
239000013598
vector
Substances
0.000
description
52
230000032258
transport
Effects
0.000
description
42
108010078791
Carrier Proteins
Proteins
0.000
description
41
108020004414
DNA
Proteins
0.000
description
41
108090000862
Ion Channels
Proteins
0.000
description
38
235000001014
amino acid
Nutrition
0.000
description
36
238000002869
basic local alignment search tool
Methods
0.000
description
33
210000004379
membrane
Anatomy
0.000
description
31
239000012528
membrane
Substances
0.000
description
31
208000035475
disorder
Diseases
0.000
description
30
229940024606
amino acid
Drugs
0.000
description
29
150000001413
amino acids
Chemical class
0.000
description
28
239000013615
primer
Substances
0.000
description
28
238000004458
analytical method
Methods
0.000
description
26
230000035772
mutation
Effects
0.000
description
26
229910001415
sodium ion
Inorganic materials
0.000
description
26
238000006467
substitution reaction
Methods
0.000
description
26
210000001519
tissue
Anatomy
0.000
description
25
FKNQFGJONOIPTF-UHFFFAOYSA-N
Sodium cation
Chemical compound
[Na+]
FKNQFGJONOIPTF-UHFFFAOYSA-N
0.000
description
24
230000006870
function
Effects
0.000
description
24
239000002299
complementary DNA
Substances
0.000
description
23
108091028043
Nucleic acid sequence
Proteins
0.000
description
22
150000002500
ions
Chemical class
0.000
description
22
238000003556
assay
Methods
0.000
description
21
239000003446
ligand
Substances
0.000
description
21
238000003752
polymerase chain reaction
Methods
0.000
description
21
230000001105
regulatory effect
Effects
0.000
description
20
208000026310
Breast neoplasm
Diseases
0.000
description
19
JLCPHMBAVCMARE-UHFFFAOYSA-N
[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
Polymers
Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O
JLCPHMBAVCMARE-UHFFFAOYSA-N
0.000
description
19
238000004422
calculation algorithm
Methods
0.000
description
19
206010006187
Breast cancer
Diseases
0.000
description
16
108020004459
Small interfering RNA
Proteins
0.000
description
16
102000014914
Carrier Proteins
Human genes
0.000
description
15
102000019298
Lipocalin
Human genes
0.000
description
15
108050006654
Lipocalin
Proteins
0.000
description
15
239000011575
calcium
Substances
0.000
description
15
230000008569
process
Effects
0.000
description
15
206010028980
Neoplasm
Diseases
0.000
description
14
230000000692
anti-sense effect
Effects
0.000
description
14
102000005962
receptors
Human genes
0.000
description
14
108020003175
receptors
Proteins
0.000
description
14
238000013518
transcription
Methods
0.000
description
14
230000035897
transcription
Effects
0.000
description
14
239000003814
drug
Substances
0.000
description
13
238000005516
engineering process
Methods
0.000
description
13
230000002068
genetic effect
Effects
0.000
description
13
238000000338
in vitro
Methods
0.000
description
13
239000011148
porous material
Substances
0.000
description
13
230000028327
secretion
Effects
0.000
description
13
230000014616
translation
Effects
0.000
description
13
ZKHQWZAMYRWXGA-UHFFFAOYSA-N
Adenosine triphosphate
Natural products
C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O
ZKHQWZAMYRWXGA-UHFFFAOYSA-N
0.000
description
12
-1
e.g.
Natural products
0.000
description
12
230000003834
intracellular effect
Effects
0.000
description
12
230000004044
response
Effects
0.000
description
12
239000011734
sodium
Substances
0.000
description
12
235000000346
sugar
Nutrition
0.000
description
12
108091023037
Aptamer
Proteins
0.000
description
11
108010026552
Proteome
Proteins
0.000
description
11
125000000539
amino acid group
Chemical group
0.000
description
11
210000000170
cell membrane
Anatomy
0.000
description
11
230000000875
corresponding effect
Effects
0.000
description
11
239000003550
marker
Substances
0.000
description
11
238000003786
synthesis reaction
Methods
0.000
description
11
238000013519
translation
Methods
0.000
description
11
BHPQYMZQTOCNFJ-UHFFFAOYSA-N
Calcium cation
Chemical compound
[Ca+2]
BHPQYMZQTOCNFJ-UHFFFAOYSA-N
0.000
description
10
241000700584
Simplexvirus
Species
0.000
description
10
229910001424
calcium ion
Inorganic materials
0.000
description
10
238000003745
diagnosis
Methods
0.000
description
10
238000001415
gene therapy
Methods
0.000
description
10
239000003112
inhibitor
Substances
0.000
description
10
108020004999
messenger RNA
Proteins
0.000
description
10
239000013612
plasmid
Substances
0.000
description
10
238000002360
preparation method
Methods
0.000
description
10
230000001225
therapeutic effect
Effects
0.000
description
10
241001430294
unidentified retrovirus
Species
0.000
description
10
102000005416
ATP-Binding Cassette Transporters
Human genes
0.000
description
9
108010006533
ATP-Binding Cassette Transporters
Proteins
0.000
description
9
102000004190
Enzymes
Human genes
0.000
description
9
108090000790
Enzymes
Proteins
0.000
description
9
208000021642
Muscular disease
Diseases
0.000
description
9
238000012228
RNA interference-mediated gene silencing
Methods
0.000
description
9
230000033228
biological regulation
Effects
0.000
description
9
230000001413
cellular effect
Effects
0.000
description
9
229940088598
enzyme
Drugs
0.000
description
9
230000009368
gene silencing by RNA
Effects
0.000
description
9
230000001900
immune effect
Effects
0.000
description
9
238000001727
in vivo
Methods
0.000
description
9
230000001939
inductive effect
Effects
0.000
description
9
210000003734
kidney
Anatomy
0.000
description
9
230000001404
mediated effect
Effects
0.000
description
9
230000004048
modification
Effects
0.000
description
9
238000012986
modification
Methods
0.000
description
9
210000003205
muscle
Anatomy
0.000
description
9
210000002569
neuron
Anatomy
0.000
description
9
238000001890
transfection
Methods
0.000
description
9
238000012546
transfer
Methods
0.000
description
9
230000003612
virological effect
Effects
0.000
description
9
102000040650
(ribonucleotides)n+m
Human genes
0.000
description
8
108700028369
Alleles
Proteins
0.000
description
8
241000710929
Alphavirus
Species
0.000
description
8
108010062745
Chloride Channels
Proteins
0.000
description
8
102000011045
Chloride Channels
Human genes
0.000
description
8
108091006671
Ion Transporter
Proteins
0.000
description
8
102000037862
Ion Transporter
Human genes
0.000
description
8
102000015636
Oligopeptides
Human genes
0.000
description
8
108010038807
Oligopeptides
Proteins
0.000
description
8
108091093037
Peptide nucleic acid
Proteins
0.000
description
8
239000013566
allergen
Substances
0.000
description
8
201000011510
cancer
Diseases
0.000
description
8
239000003795
chemical substances by application
Substances
0.000
description
8
238000012217
deletion
Methods
0.000
description
8
230000037430
deletion
Effects
0.000
description
8
108020001507
fusion proteins
Proteins
0.000
description
8
102000037865
fusion proteins
Human genes
0.000
description
8
230000013595
glycosylation
Effects
0.000
description
8
238000006206
glycosylation reaction
Methods
0.000
description
8
230000028993
immune response
Effects
0.000
description
8
238000012163
sequencing technique
Methods
0.000
description
8
150000003384
small molecules
Chemical class
0.000
description
8
241000894007
species
Species
0.000
description
8
239000000126
substance
Substances
0.000
description
8
108090000994
Catalytic RNA
Proteins
0.000
description
7
102000053642
Catalytic RNA
Human genes
0.000
description
7
241000282412
Homo
Species
0.000
description
7
241000124008
Mammalia
Species
0.000
description
7
241000699666
Mus <mouse, genus>
Species
0.000
description
7
201000009623
Myopathy
Diseases
0.000
description
7
241000700159
Rattus
Species
0.000
description
7
238000007792
addition
Methods
0.000
description
7
230000003321
amplification
Effects
0.000
description
7
238000003776
cleavage reaction
Methods
0.000
description
7
229940079593
drug
Drugs
0.000
description
7
239000002502
liposome
Substances
0.000
description
7
238000003199
nucleic acid amplification method
Methods
0.000
description
7
108091092562
ribozyme
Proteins
0.000
description
7
230000007017
scission
Effects
0.000
description
7
239000000243
solution
Substances
0.000
description
7
208000011580
syndromic disease
Diseases
0.000
description
7
238000002560
therapeutic procedure
Methods
0.000
description
7
230000009466
transformation
Effects
0.000
description
7
241000701161
unidentified adenovirus
Species
0.000
description
7
108091006112
ATPases
Proteins
0.000
description
6
102000057290
Adenosine Triphosphatases
Human genes
0.000
description
6
108091026890
Coding region
Proteins
0.000
description
6
201000003883
Cystic fibrosis
Diseases
0.000
description
6
102000053602
DNA
Human genes
0.000
description
6
241000196324
Embryophyta
Species
0.000
description
6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Ethanol
Chemical compound
CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
6
DGAQECJNVWCQMB-PUAWFVPOSA-M
Ilexoside XXIX
Chemical compound
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+]
DGAQECJNVWCQMB-PUAWFVPOSA-M
0.000
description
6
206010061218
Inflammation
Diseases
0.000
description
6
102000015841
Major facilitator superfamily
Human genes
0.000
description
6
108050004064
Major facilitator superfamily
Proteins
0.000
description
6
206010061535
Ovarian neoplasm
Diseases
0.000
description
6
102000018674
Sodium Channels
Human genes
0.000
description
6
108010052164
Sodium Channels
Proteins
0.000
description
6
108091081024
Start codon
Proteins
0.000
description
6
ISAKRJDGNUQOIC-UHFFFAOYSA-N
Uracil
Chemical group
O=C1C=CNC(=O)N1
ISAKRJDGNUQOIC-UHFFFAOYSA-N
0.000
description
6
239000000427
antigen
Substances
0.000
description
6
108091007433
antigens
Proteins
0.000
description
6
102000036639
antigens
Human genes
0.000
description
6
230000001580
bacterial effect
Effects
0.000
description
6
230000004071
biological effect
Effects
0.000
description
6
208000029742
colonic neoplasm
Diseases
0.000
description
6
238000010276
construction
Methods
0.000
description
6
230000001086
cytosolic effect
Effects
0.000
description
6
239000003623
enhancer
Substances
0.000
description
6
238000003018
immunoassay
Methods
0.000
description
6
208000015181
infectious disease
Diseases
0.000
description
6
230000004054
inflammatory process
Effects
0.000
description
6
230000007246
mechanism
Effects
0.000
description
6
230000000926
neurological effect
Effects
0.000
description
6
210000003463
organelle
Anatomy
0.000
description
6
230000026731
phosphorylation
Effects
0.000
description
6
238000006366
phosphorylation reaction
Methods
0.000
description
6
239000002987
primer (paints)
Substances
0.000
description
6
230000002062
proliferating effect
Effects
0.000
description
6
238000000746
purification
Methods
0.000
description
6
230000010076
replication
Effects
0.000
description
6
230000000284
resting effect
Effects
0.000
description
6
229910052708
sodium
Inorganic materials
0.000
description
6
150000008163
sugars
Chemical class
0.000
description
6
RWQNBRDOKXIBIV-UHFFFAOYSA-N
thymine
Chemical compound
CC1=CNC(=O)NC1=O
RWQNBRDOKXIBIV-UHFFFAOYSA-N
0.000
description
6
MTCFGRXMJLQNBG-REOHCLBHSA-N
(2S)-2-Amino-3-hydroxypropansäure
Chemical compound
OC[C@H](N)C(O)=O
MTCFGRXMJLQNBG-REOHCLBHSA-N
0.000
description
5
108010068806
Acid Sensing Ion Channels
Proteins
0.000
description
5
102000001671
Acid Sensing Ion Channels
Human genes
0.000
description
5
108010025614
Apolipoproteins D
Proteins
0.000
description
5
108020004705
Codon
Proteins
0.000
description
5
206010009944
Colon cancer
Diseases
0.000
description
5
108700024394
Exon
Proteins
0.000
description
5
WQZGKKKJIJFFOK-GASJEMHNSA-N
Glucose
Natural products
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
WQZGKKKJIJFFOK-GASJEMHNSA-N
0.000
description
5
208000015023
Graves' disease
Diseases
0.000
description
5
WHUUTDBJXJRKMK-VKHMYHEASA-N
L-glutamic acid
Chemical compound
OC(=O)[C@@H](N)CCC(O)=O
WHUUTDBJXJRKMK-VKHMYHEASA-N
0.000
description
5
241000283973
Oryctolagus cuniculus
Species
0.000
description
5
240000004808
Saccharomyces cerevisiae
Species
0.000
description
5
DBMJMQXJHONAFJ-UHFFFAOYSA-M
Sodium laurylsulphate
Chemical compound
[Na+].CCCCCCCCCCCCOS([O-])(=O)=O
DBMJMQXJHONAFJ-UHFFFAOYSA-M
0.000
description
5
238000010171
animal model
Methods
0.000
description
5
108091008324
binding proteins
Proteins
0.000
description
5
230000003185
calcium uptake
Effects
0.000
description
5
230000000747
cardiac effect
Effects
0.000
description
5
239000003153
chemical reaction reagent
Substances
0.000
description
5
210000000349
chromosome
Anatomy
0.000
description
5
230000007812
deficiency
Effects
0.000
description
5
238000001514
detection method
Methods
0.000
description
5
238000011161
development
Methods
0.000
description
5
230000018109
developmental process
Effects
0.000
description
5
102000052116
epidermal growth factor receptor activity proteins
Human genes
0.000
description
5
108700015053
epidermal growth factor receptor activity proteins
Proteins
0.000
description
5
206010015037
epilepsy
Diseases
0.000
description
5
210000002919
epithelial cell
Anatomy
0.000
description
5
238000009472
formulation
Methods
0.000
description
5
239000008103
glucose
Substances
0.000
description
5
230000002209
hydrophobic effect
Effects
0.000
description
5
238000003780
insertion
Methods
0.000
description
5
230000037431
insertion
Effects
0.000
description
5
210000004185
liver
Anatomy
0.000
description
5
230000028161
membrane depolarization
Effects
0.000
description
5
229910021645
metal ion
Inorganic materials
0.000
description
5
YOHYSYJDKVYCJI-UHFFFAOYSA-N
n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide
Chemical compound
FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1
YOHYSYJDKVYCJI-UHFFFAOYSA-N
0.000
description
5
238000004806
packaging method and process
Methods
0.000
description
5
230000037361
pathway
Effects
0.000
description
5
230000032361
posttranscriptional gene silencing
Effects
0.000
description
5
238000012545
processing
Methods
0.000
description
5
239000000047
product
Substances
0.000
description
5
238000002864
sequence alignment
Methods
0.000
description
5
210000002027
skeletal muscle
Anatomy
0.000
description
5
241001529453
unidentified herpesvirus
Species
0.000
description
5
239000013603
viral vector
Substances
0.000
description
5
102100024643
ATP-binding cassette sub-family D member 1
Human genes
0.000
description
4
102000013933
Apolipoproteins D
Human genes
0.000
description
4
OYPRJOBELJOOCE-UHFFFAOYSA-N
Calcium
Chemical compound
[Ca]
OYPRJOBELJOOCE-UHFFFAOYSA-N
0.000
description
4
108091005462
Cation channels
Proteins
0.000
description
4
102100023321
Ceruloplasmin
Human genes
0.000
description
4
108020004635
Complementary DNA
Proteins
0.000
description
4
108091035707
Consensus sequence
Proteins
0.000
description
4
206010013801
Duchenne Muscular Dystrophy
Diseases
0.000
description
4
241000283073
Equus caballus
Species
0.000
description
4
108010055870
Fatty Acid Transport Proteins
Proteins
0.000
description
4
102000000476
Fatty Acid Transport Proteins
Human genes
0.000
description
4
WHUUTDBJXJRKMK-UHFFFAOYSA-N
Glutamic acid
Natural products
OC(=O)C(N)CCC(O)=O
WHUUTDBJXJRKMK-UHFFFAOYSA-N
0.000
description
4
DHMQDGOQFOQNFH-UHFFFAOYSA-N
Glycine
Chemical compound
NCC(O)=O
DHMQDGOQFOQNFH-UHFFFAOYSA-N
0.000
description
4
208000003807
Graves Disease
Diseases
0.000
description
4
208000026350
Inborn Genetic disease
Diseases
0.000
description
4
KDXKERNSBIXSRK-UHFFFAOYSA-N
Lysine
Natural products
NCCCCC(N)C(O)=O
KDXKERNSBIXSRK-UHFFFAOYSA-N
0.000
description
4
241000699670
Mus sp.
Species
0.000
description
4
208000010316
Myotonia congenita
Diseases
0.000
description
4
206010033128
Ovarian cancer
Diseases
0.000
description
4
102000004257
Potassium Channel
Human genes
0.000
description
4
108091028664
Ribonucleotide
Proteins
0.000
description
4
241000714474
Rous sarcoma virus
Species
0.000
description
4
235000014680
Saccharomyces cerevisiae
Nutrition
0.000
description
4
238000012300
Sequence Analysis
Methods
0.000
description
4
108091027967
Small hairpin RNA
Proteins
0.000
description
4
241000282887
Suidae
Species
0.000
description
4
210000001744
T-lymphocyte
Anatomy
0.000
description
4
241000700605
Viruses
Species
0.000
description
4
230000036982
action potential
Effects
0.000
description
4
XSDQTOBWRPYKKA-UHFFFAOYSA-N
amiloride
Chemical compound
NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N
XSDQTOBWRPYKKA-UHFFFAOYSA-N
0.000
description
4
229960002576
amiloride
Drugs
0.000
description
4
238000000137
annealing
Methods
0.000
description
4
230000000890
antigenic effect
Effects
0.000
description
4
238000013459
approach
Methods
0.000
description
4
210000004369
blood
Anatomy
0.000
description
4
239000008280
blood
Substances
0.000
description
4
210000004556
brain
Anatomy
0.000
description
4
210000000481
breast
Anatomy
0.000
description
4
229910052791
calcium
Inorganic materials
0.000
description
4
150000001720
carbohydrates
Chemical class
0.000
description
4
235000014633
carbohydrates
Nutrition
0.000
description
4
125000003178
carboxy group
Chemical group
[H]OC(*)=O
0.000
description
4
238000004113
cell culture
Methods
0.000
description
4
210000003169
central nervous system
Anatomy
0.000
description
4
238000010367
cloning
Methods
0.000
description
4
125000004122
cyclic group
Chemical class
0.000
description
4
230000034994
death
Effects
0.000
description
4
231100000517
death
Toxicity
0.000
description
4
230000007547
defect
Effects
0.000
description
4
201000001981
dermatomyositis
Diseases
0.000
description
4
VZFRNCSOCOPNDB-UHFFFAOYSA-N
domoic acid
Natural products
OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O
VZFRNCSOCOPNDB-UHFFFAOYSA-N
0.000
description
4
230000002124
endocrine
Effects
0.000
description
4
230000002255
enzymatic effect
Effects
0.000
description
4
239000000284
extract
Substances
0.000
description
4
UYTPUPDQBNUYGX-UHFFFAOYSA-N
guanine
Chemical compound
O=C1NC(N)=NC2=C1N=CN2
UYTPUPDQBNUYGX-UHFFFAOYSA-N
0.000
description
4
230000007062
hydrolysis
Effects
0.000
description
4
238000006460
hydrolysis reaction
Methods
0.000
description
4
230000005764
inhibitory process
Effects
0.000
description
4
NOESYZHRGYRDHS-UHFFFAOYSA-N
insulin
Chemical compound
N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1
NOESYZHRGYRDHS-UHFFFAOYSA-N
0.000
description
4
108010045069
keyhole-limpet hemocyanin
Proteins
0.000
description
4
208000020816
lung neoplasm
Diseases
0.000
description
4
229920002521
macromolecule
Polymers
0.000
description
4
239000000463
material
Substances
0.000
description
4
239000011159
matrix material
Substances
0.000
description
4
230000004118
muscle contraction
Effects
0.000
description
4
239000002858
neurotransmitter agent
Substances
0.000
description
4
210000003819
peripheral blood mononuclear cell
Anatomy
0.000
description
4
229920000642
polymer
Polymers
0.000
description
4
102000054765
polymorphisms of proteins
Human genes
0.000
description
4
208000005987
polymyositis
Diseases
0.000
description
4
108020001213
potassium channel
Proteins
0.000
description
4
230000002265
prevention
Effects
0.000
description
4
125000002924
primary amino group
Chemical group
[H]N([H])*
0.000
description
4
230000002685
pulmonary effect
Effects
0.000
description
4
238000003127
radioimmunoassay
Methods
0.000
description
4
239000002336
ribonucleotide
Substances
0.000
description
4
125000002652
ribonucleotide group
Chemical group
0.000
description
4
230000003248
secreting effect
Effects
0.000
description
4
230000035945
sensitivity
Effects
0.000
description
4
230000001988
toxicity
Effects
0.000
description
4
231100000419
toxicity
Toxicity
0.000
description
4
241000972773
Aulopiformes
Species
0.000
description
3
208000031212
Autoimmune polyendocrinopathy
Diseases
0.000
description
3
241000894006
Bacteria
Species
0.000
description
3
241000283690
Bos taurus
Species
0.000
description
3
108090000312
Calcium Channels
Proteins
0.000
description
3
102000003922
Calcium Channels
Human genes
0.000
description
3
102000034573
Channels
Human genes
0.000
description
3
208000001333
Colorectal Neoplasms
Diseases
0.000
description
3
RYGMFSIKBFXOCR-UHFFFAOYSA-N
Copper
Chemical compound
[Cu]
RYGMFSIKBFXOCR-UHFFFAOYSA-N
0.000
description
3
238000001712
DNA sequencing
Methods
0.000
description
3
108010033806
Degenerin Sodium Channels
Proteins
0.000
description
3
238000002965
ELISA
Methods
0.000
description
3
108010008165
Etanercept
Proteins
0.000
description
3
108091052347
Glucose transporter family
Proteins
0.000
description
3
102000005720
Glutathione transferase
Human genes
0.000
description
3
108010070675
Glutathione transferase
Proteins
0.000
description
3
206010020751
Hypersensitivity
Diseases
0.000
description
3
XQFRJNBWHJMXHO-RRKCRQDMSA-N
IDUR
Chemical compound
C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1
XQFRJNBWHJMXHO-RRKCRQDMSA-N
0.000
description
3
ROHFNLRQFUQHCH-YFKPBYRVSA-N
L-leucine
Chemical compound
CC(C)C[C@H](N)C(O)=O
ROHFNLRQFUQHCH-YFKPBYRVSA-N
0.000
description
3
108091026898
Leader sequence (mRNA)
Proteins
0.000
description
3
108090000543
Ligand-Gated Ion Channels
Proteins
0.000
description
3
102000004086
Ligand-Gated Ion Channels
Human genes
0.000
description
3
206010058467
Lung neoplasm malignant
Diseases
0.000
description
3
239000004472
Lysine
Substances
0.000
description
3
206010064912
Malignant transformation
Diseases
0.000
description
3
101710175625
Maltose/maltodextrin-binding periplasmic protein
Proteins
0.000
description
3
108010049137
Member 1 Subfamily D ATP Binding Cassette Transporter
Proteins
0.000
description
3
108010052285
Membrane Proteins
Proteins
0.000
description
3
206010027476
Metastases
Diseases
0.000
description
3
206010061309
Neoplasm progression
Diseases
0.000
description
3
208000012902
Nervous system disease
Diseases
0.000
description
3
108091005461
Nucleic proteins
Proteins
0.000
description
3
108010029485
Protein Isoforms
Proteins
0.000
description
3
102000001708
Protein Isoforms
Human genes
0.000
description
3
102000001253
Protein Kinase
Human genes
0.000
description
3
108020004511
Recombinant DNA
Proteins
0.000
description
3
206010039491
Sarcoma
Diseases
0.000
description
3
241000710961
Semliki Forest virus
Species
0.000
description
3
102000018692
Sulfonylurea Receptors
Human genes
0.000
description
3
108010091821
Sulfonylurea Receptors
Proteins
0.000
description
3
108091036066
Three prime untranslated region
Proteins
0.000
description
3
241000723873
Tobacco mosaic virus
Species
0.000
description
3
108700025716
Tumor Suppressor Genes
Proteins
0.000
description
3
102000044209
Tumor Suppressor Genes
Human genes
0.000
description
3
108091023045
Untranslated Region
Proteins
0.000
description
3
241000700618
Vaccinia virus
Species
0.000
description
3
230000002159
abnormal effect
Effects
0.000
description
3
230000009471
action
Effects
0.000
description
3
230000004913
activation
Effects
0.000
description
3
239000004480
active ingredient
Substances
0.000
description
3
239000002671
adjuvant
Substances
0.000
description
3
230000003110
anti-inflammatory effect
Effects
0.000
description
3
206010003119
arrhythmia
Diseases
0.000
description
3
208000006673
asthma
Diseases
0.000
description
3
229940092705
beclomethasone
Drugs
0.000
description
3
NBMKJKDGKREAPL-DVTGEIKXSA-N
beclomethasone
Chemical compound
C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O
NBMKJKDGKREAPL-DVTGEIKXSA-N
0.000
description
3
210000002459
blastocyst
Anatomy
0.000
description
3
210000001124
body fluid
Anatomy
0.000
description
3
239000000969
carrier
Substances
0.000
description
3
230000004663
cell proliferation
Effects
0.000
description
3
238000006243
chemical reaction
Methods
0.000
description
3
208000029664
classic familial adenomatous polyposis
Diseases
0.000
description
3
230000009918
complex formation
Effects
0.000
description
3
229910052802
copper
Inorganic materials
0.000
description
3
239000010949
copper
Substances
0.000
description
3
210000000172
cytosol
Anatomy
0.000
description
3
230000007423
decrease
Effects
0.000
description
3
230000001419
dependent effect
Effects
0.000
description
3
206010012601
diabetes mellitus
Diseases
0.000
description
3
238000001943
fluorescence-activated cell sorting
Methods
0.000
description
3
BTCSSZJGUNDROE-UHFFFAOYSA-N
gamma-aminobutyric acid
Chemical compound
NCCCC(O)=O
BTCSSZJGUNDROE-UHFFFAOYSA-N
0.000
description
3
238000001476
gene delivery
Methods
0.000
description
3
230000030279
gene silencing
Effects
0.000
description
3
208000016361
genetic disease
Diseases
0.000
description
3
238000010353
genetic engineering
Methods
0.000
description
3
239000003862
glucocorticoid
Substances
0.000
description
3
238000002744
homologous recombination
Methods
0.000
description
3
230000006801
homologous recombination
Effects
0.000
description
3
210000000688
human artificial chromosome
Anatomy
0.000
description
3
230000000977
initiatory effect
Effects
0.000
description
3
238000002347
injection
Methods
0.000
description
3
239000007924
injection
Substances
0.000
description
3
230000003993
interaction
Effects
0.000
description
3
230000033001
locomotion
Effects
0.000
description
3
230000007774
longterm
Effects
0.000
description
3
201000005202
lung cancer
Diseases
0.000
description
3
238000012423
maintenance
Methods
0.000
description
3
229940049920
malate
Drugs
0.000
description
3
BJEPYKJPYRNKOW-UHFFFAOYSA-L
malate(2-)
Chemical compound
[O-]C(=O)C(O)CC([O-])=O
BJEPYKJPYRNKOW-UHFFFAOYSA-L
0.000
description
3
230000036212
malign transformation
Effects
0.000
description
3
210000004962
mammalian cell
Anatomy
0.000
description
3
201000001441
melanoma
Diseases
0.000
description
3
239000002207
metabolite
Substances
0.000
description
3
230000036457
multidrug resistance
Effects
0.000
description
3
201000006417
multiple sclerosis
Diseases
0.000
description
3
206010028417
myasthenia gravis
Diseases
0.000
description
3
210000004165
myocardium
Anatomy
0.000
description
3
210000000056
organ
Anatomy
0.000
description
3
239000008177
pharmaceutical agent
Substances
0.000
description
3
239000002243
precursor
Substances
0.000
description
3
230000000644
propagated effect
Effects
0.000
description
3
230000006798
recombination
Effects
0.000
description
3
238000011160
research
Methods
0.000
description
3
108091000053
retinol binding
Proteins
0.000
description
3
102000029752
retinol binding
Human genes
0.000
description
3
235000019515
salmon
Nutrition
0.000
description
3
230000035939
shock
Effects
0.000
description
3
230000011664
signaling
Effects
0.000
description
3
230000000638
stimulation
Effects
0.000
description
3
230000004083
survival effect
Effects
0.000
description
3
229940113082
thymine
Drugs
0.000
description
3
210000001685
thyroid gland
Anatomy
0.000
description
3
230000002103
transcriptional effect
Effects
0.000
description
3
238000010361
transduction
Methods
0.000
description
3
230000026683
transduction
Effects
0.000
description
3
230000001052
transient effect
Effects
0.000
description
3
230000005751
tumor progression
Effects
0.000
description
3
229940035893
uracil
Drugs
0.000
description
3
238000005406
washing
Methods
0.000
description
3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N
(+)-Biotin
Chemical compound
N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21
YBJHBAHKTGYVGT-ZKWXMUAHSA-N
0.000
description
2
ASJSAQIRZKANQN-CRCLSJGQSA-N
2-deoxy-D-ribose
Chemical compound
OC[C@@H](O)[C@@H](O)CC=O
ASJSAQIRZKANQN-CRCLSJGQSA-N
0.000
description
2
101710169336
5'-deoxyadenosine deaminase
Proteins
0.000
description
2
208000030507
AIDS
Diseases
0.000
description
2
108010062271
Acute-Phase Proteins
Proteins
0.000
description
2
102000011767
Acute-Phase Proteins
Human genes
0.000
description
2
208000026872
Addison Disease
Diseases
0.000
description
2
102000055025
Adenosine deaminases
Human genes
0.000
description
2
201000011452
Adrenoleukodystrophy
Diseases
0.000
description
2
208000007887
Alphavirus Infections
Diseases
0.000
description
2
208000024827
Alzheimer disease
Diseases
0.000
description
2
208000000044
Amnesia
Diseases
0.000
description
2
208000031091
Amnestic disease
Diseases
0.000
description
2
206010002383
Angina Pectoris
Diseases
0.000
description
2
102000000412
Annexin
Human genes
0.000
description
2
108050008874
Annexin
Proteins
0.000
description
2
235000002198
Annona diversifolia
Nutrition
0.000
description
2
208000019901
Anxiety disease
Diseases
0.000
description
2
102000010637
Aquaporins
Human genes
0.000
description
2
108010063290
Aquaporins
Proteins
0.000
description
2
201000001320
Atherosclerosis
Diseases
0.000
description
2
102100036465
Autoimmune regulator
Human genes
0.000
description
2
208000012904
Bartter disease
Diseases
0.000
description
2
208000010062
Bartter syndrome
Diseases
0.000
description
2
241001674044
Blattodea
Species
0.000
description
2
241000282832
Camelidae
Species
0.000
description
2
241000282472
Canis lupus familiaris
Species
0.000
description
2
108090000565
Capsid Proteins
Proteins
0.000
description
2
208000031229
Cardiomyopathies
Diseases
0.000
description
2
102100025064
Cellular tumor antigen p53
Human genes
0.000
description
2
201000003728
Centronuclear myopathy
Diseases
0.000
description
2
241000282693
Cercopithecidae
Species
0.000
description
2
206010053684
Cerebrohepatorenal syndrome
Diseases
0.000
description
2
108010075016
Ceruloplasmin
Proteins
0.000
description
2
108700010070
Codon Usage
Proteins
0.000
description
2
206010010099
Combined immunodeficiency
Diseases
0.000
description
2
206010010904
Convulsion
Diseases
0.000
description
2
102000034534
Cotransporters
Human genes
0.000
description
2
108020003264
Cotransporters
Proteins
0.000
description
2
206010011778
Cystinuria
Diseases
0.000
description
2
241000701022
Cytomegalovirus
Species
0.000
description
2
HMFHBZSHGGEWLO-SOOFDHNKSA-N
D-ribofuranose
Chemical compound
OC[C@H]1OC(O)[C@H](O)[C@@H]1O
HMFHBZSHGGEWLO-SOOFDHNKSA-N
0.000
description
2
108010017826
DNA Polymerase I
Proteins
0.000
description
2
102000004594
DNA Polymerase I
Human genes
0.000
description
2
102000004163
DNA-directed RNA polymerases
Human genes
0.000
description
2
108090000626
DNA-directed RNA polymerases
Proteins
0.000
description
2
206010012289
Dementia
Diseases
0.000
description
2
208000032131
Diabetic Neuropathies
Diseases
0.000
description
2
241000255581
Drosophila <fruit fly, genus>
Species
0.000
description
2
101000771077
Drosophila melanogaster Cyclic nucleotide-gated cation channel subunit A
Proteins
0.000
description
2
102000001301
EGF receptor
Human genes
0.000
description
2
108060006698
EGF receptor
Proteins
0.000
description
2
108010042407
Endonucleases
Proteins
0.000
description
2
241001635598
Enicostema
Species
0.000
description
2
241000283086
Equidae
Species
0.000
description
2
241000588724
Escherichia coli
Species
0.000
description
2
102000018711
Facilitative Glucose Transport Proteins
Human genes
0.000
description
2
201000006107
Familial adenomatous polyposis
Diseases
0.000
description
2
208000010541
Familial or sporadic hemiplegic migraine
Diseases
0.000
description
2
ZHNUHDYFZUAESO-UHFFFAOYSA-N
Formamide
Chemical compound
NC=O
ZHNUHDYFZUAESO-UHFFFAOYSA-N
0.000
description
2
201000011240
Frontotemporal dementia
Diseases
0.000
description
2
102000042092
Glucose transporter family
Human genes
0.000
description
2
239000004471
Glycine
Substances
0.000
description
2
208000032003
Glycogen storage disease due to glucose-6-phosphatase deficiency
Diseases
0.000
description
2
206010018464
Glycogen storage disease type I
Diseases
0.000
description
2
206010053185
Glycogen storage disease type II
Diseases
0.000
description
2
108020004202
Guanylate Kinase
Proteins
0.000
description
2
102000015779
HDL Lipoproteins
Human genes
0.000
description
2
108010010234
HDL Lipoproteins
Proteins
0.000
description
2
208000030836
Hashimoto thyroiditis
Diseases
0.000
description
2
206010019476
Hemiplegic migraine
Diseases
0.000
description
2
208000009292
Hemophilia A
Diseases
0.000
description
2
101000928549
Homo sapiens Autoimmune regulator
Proteins
0.000
description
2
101001047090
Homo sapiens Potassium voltage-gated channel subfamily H member 2
Proteins
0.000
description
2
101000693890
Homo sapiens Sodium-dependent multivitamin transporter
Proteins
0.000
description
2
241000725303
Human immunodeficiency virus
Species
0.000
description
2
208000035150
Hypercholesterolemia
Diseases
0.000
description
2
206010020772
Hypertension
Diseases
0.000
description
2
206010020844
Hyperthermia malignant
Diseases
0.000
description
2
208000013016
Hypoglycemia
Diseases
0.000
description
2
208000010317
Iminoglycinuria
Diseases
0.000
description
2
102000004877
Insulin
Human genes
0.000
description
2
108090001061
Insulin
Proteins
0.000
description
2
XEEYBQQBJWHFJM-UHFFFAOYSA-N
Iron
Chemical compound
[Fe]
XEEYBQQBJWHFJM-UHFFFAOYSA-N
0.000
description
2
DCXYFEDJOCDNAF-REOHCLBHSA-N
L-asparagine
Chemical compound
OC(=O)[C@@H](N)CC(N)=O
DCXYFEDJOCDNAF-REOHCLBHSA-N
0.000
description
2
JVTAAEKCZFNVCJ-REOHCLBHSA-N
L-lactic acid
Chemical compound
C[C@H](O)C(O)=O
JVTAAEKCZFNVCJ-REOHCLBHSA-N
0.000
description
2
COLNVLDHVKWLRT-QMMMGPOBSA-N
L-phenylalanine
Chemical compound
OC(=O)[C@@H](N)CC1=CC=CC=C1
COLNVLDHVKWLRT-QMMMGPOBSA-N
0.000
description
2
AYFVYJQAPQTCCC-GBXIJSLDSA-N
L-threonine
Chemical compound
C[C@@H](O)[C@H](N)C(O)=O
AYFVYJQAPQTCCC-GBXIJSLDSA-N
0.000
description
2
102000007330
LDL Lipoproteins
Human genes
0.000
description
2
108010007622
LDL Lipoproteins
Proteins
0.000
description
2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M
Lactate
Chemical compound
CC(O)C([O-])=O
JVTAAEKCZFNVCJ-UHFFFAOYSA-M
0.000
description
2
241000282838
Lama
Species
0.000
description
2
208000026709
Liddle syndrome
Diseases
0.000
description
2
208000018717
Malignant hyperthermia of anesthesia
Diseases
0.000
description
2
108010050258
Mitochondrial Uncoupling Proteins
Proteins
0.000
description
2
102000015494
Mitochondrial Uncoupling Proteins
Human genes
0.000
description
2
201000002169
Mitochondrial myopathy
Diseases
0.000
description
2
208000003250
Mixed connective tissue disease
Diseases
0.000
description
2
241001529936
Murinae
Species
0.000
description
2
208000029578
Muscle disease
Diseases
0.000
description
2
101710135898
Myc proto-oncogene protein
Proteins
0.000
description
2
102100038895
Myc proto-oncogene protein
Human genes
0.000
description
2
208000009525
Myocarditis
Diseases
0.000
description
2
201000002481
Myositis
Diseases
0.000
description
2
206010061533
Myotonia
Diseases
0.000
description
2
206010068871
Myotonic dystrophy
Diseases
0.000
description
2
208000034965
Nemaline Myopathies
Diseases
0.000
description
2
208000009905
Neurofibromatoses
Diseases
0.000
description
2
208000025966
Neurological disease
Diseases
0.000
description
2
PXHVJJICTQNCMI-UHFFFAOYSA-N
Nickel
Chemical compound
[Ni]
PXHVJJICTQNCMI-UHFFFAOYSA-N
0.000
description
2
108700026244
Open Reading Frames
Proteins
0.000
description
2
229910019142
PO4
Inorganic materials
0.000
description
2
208000002193
Pain
Diseases
0.000
description
2
208000027099
Paranoid disease
Diseases
0.000
description
2
208000018737
Parkinson disease
Diseases
0.000
description
2
102000004861
Phosphoric Diester Hydrolases
Human genes
0.000
description
2
108090001050
Phosphoric Diester Hydrolases
Proteins
0.000
description
2
206010036376
Postherpetic Neuralgia
Diseases
0.000
description
2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
Potassium
Chemical compound
[K]
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
0.000
description
2
102100022807
Potassium voltage-gated channel subfamily H member 2
Human genes
0.000
description
2
102000029797
Prion
Human genes
0.000
description
2
108091000054
Prion
Proteins
0.000
description
2
RJKFOVLPORLFTN-LEKSSAKUSA-N
Progesterone
Chemical compound
C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2
RJKFOVLPORLFTN-LEKSSAKUSA-N
0.000
description
2
201000004681
Psoriasis
Diseases
0.000
description
2
LCTONWCANYUPML-UHFFFAOYSA-M
Pyruvate
Chemical compound
CC(=O)C([O-])=O
LCTONWCANYUPML-UHFFFAOYSA-M
0.000
description
2
102000006382
Ribonucleases
Human genes
0.000
description
2
108010083644
Ribonucleases
Proteins
0.000
description
2
PYMYPHUHKUWMLA-LMVFSUKVSA-N
Ribose
Natural products
OC[C@@H](O)[C@@H](O)[C@@H](O)C=O
PYMYPHUHKUWMLA-LMVFSUKVSA-N
0.000
description
2
241000710960
Sindbis virus
Species
0.000
description
2
206010041067
Small cell lung cancer
Diseases
0.000
description
2
102100027046
Sodium-dependent multivitamin transporter
Human genes
0.000
description
2
208000032978
Structural Congenital Myopathies
Diseases
0.000
description
2
108091027544
Subgenomic mRNA
Proteins
0.000
description
2
108090000088
Symporters
Proteins
0.000
description
2
102000003673
Symporters
Human genes
0.000
description
2
206010043118
Tardive Dyskinesia
Diseases
0.000
description
2
102000006601
Thymidine Kinase
Human genes
0.000
description
2
108020004440
Thymidine kinase
Proteins
0.000
description
2
208000000323
Tourette Syndrome
Diseases
0.000
description
2
208000016620
Tourette disease
Diseases
0.000
description
2
108091023040
Transcription factor
Proteins
0.000
description
2
102000040945
Transcription factor
Human genes
0.000
description
2
101710150448
Transcriptional regulator Myc
Proteins
0.000
description
2
108060008682
Tumor Necrosis Factor
Proteins
0.000
description
2
KZSNJWFQEVHDMF-UHFFFAOYSA-N
Valine
Natural products
CC(C)C(N)C(O)=O
KZSNJWFQEVHDMF-UHFFFAOYSA-N
0.000
description
2
108010067390
Viral Proteins
Proteins
0.000
description
2
208000036142
Viral infection
Diseases
0.000
description
2
201000004525
Zellweger Syndrome
Diseases
0.000
description
2
208000036813
Zellweger spectrum disease
Diseases
0.000
description
2
MMWCIQZXVOZEGG-HOZKJCLWSA-N
[(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
Chemical compound
O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O
MMWCIQZXVOZEGG-HOZKJCLWSA-N
0.000
description
2
230000005856
abnormality
Effects
0.000
description
2
230000021736
acetylation
Effects
0.000
description
2
238000006640
acetylation reaction
Methods
0.000
description
2
OIPILFWXSMYKGL-UHFFFAOYSA-N
acetylcholine
Chemical compound
CC(=O)OCC[N+](C)(C)C
OIPILFWXSMYKGL-UHFFFAOYSA-N
0.000
description
2
239000002253
acid
Substances
0.000
description
2
230000003213
activating effect
Effects
0.000
description
2
208000009956
adenocarcinoma
Diseases
0.000
description
2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N
all-trans-retinol
Chemical compound
OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
FPIPGXGPPPQFEQ-OVSJKPMPSA-N
0.000
description
2
230000007815
allergy
Effects
0.000
description
2
HMFHBZSHGGEWLO-UHFFFAOYSA-N
alpha-D-Furanose-Ribose
Natural products
OCC1OC(O)C(O)C1O
HMFHBZSHGGEWLO-UHFFFAOYSA-N
0.000
description
2
230000006986
amnesia
Effects
0.000
description
2
206010002026
amyotrophic lateral sclerosis
Diseases
0.000
description
2
208000003455
anaphylaxis
Diseases
0.000
description
2
210000004102
animal cell
Anatomy
0.000
description
2
150000001450
anions
Chemical class
0.000
description
2
230000002337
anti-port
Effects
0.000
description
2
239000000074
antisense oligonucleotide
Substances
0.000
description
2
238000012230
antisense oligonucleotides
Methods
0.000
description
2
230000036506
anxiety
Effects
0.000
description
2
239000007864
aqueous solution
Substances
0.000
description
2
YZXBAPSDXZZRGB-DOFZRALJSA-N
arachidonic acid
Chemical compound
CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
YZXBAPSDXZZRGB-DOFZRALJSA-N
0.000
description
2
238000003491
array
Methods
0.000
description
2
230000006793
arrhythmia
Effects
0.000
description
2
201000009771
autoimmune polyendocrine syndrome type 1
Diseases
0.000
description
2
208000033654
autosomal recessive myotonia congenita
Diseases
0.000
description
2
210000003719
b-lymphocyte
Anatomy
0.000
description
2
230000003115
biocidal effect
Effects
0.000
description
2
230000008827
biological function
Effects
0.000
description
2
230000008236
biological pathway
Effects
0.000
description
2
210000000625
blastula
Anatomy
0.000
description
2
230000000903
blocking effect
Effects
0.000
description
2
239000010839
body fluid
Substances
0.000
description
2
201000008275
breast carcinoma
Diseases
0.000
description
2
210000004899
c-terminal region
Anatomy
0.000
description
2
238000005251
capillar electrophoresis
Methods
0.000
description
2
YKPUWZUDDOIDPM-SOFGYWHQSA-N
capsaicin
Chemical compound
COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O
YKPUWZUDDOIDPM-SOFGYWHQSA-N
0.000
description
2
231100000504
carcinogenesis
Toxicity
0.000
description
2
210000004413
cardiac myocyte
Anatomy
0.000
description
2
206010007776
catatonia
Diseases
0.000
description
2
230000003915
cell function
Effects
0.000
description
2
238000007385
chemical modification
Methods
0.000
description
2
238000002512
chemotherapy
Methods
0.000
description
2
HVYWMOMLDIMFJA-DPAQBDIFSA-N
cholesterol
Chemical compound
C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2
HVYWMOMLDIMFJA-DPAQBDIFSA-N
0.000
description
2
208000025302
chronic primary adrenal insufficiency
Diseases
0.000
description
2
229910017052
cobalt
Inorganic materials
0.000
description
2
239000010941
cobalt
Substances
0.000
description
2
GUTLYIVDDKVIGB-UHFFFAOYSA-N
cobalt atom
Chemical compound
[Co]
GUTLYIVDDKVIGB-UHFFFAOYSA-N
0.000
description
2
210000001072
colon
Anatomy
0.000
description
2
238000012875
competitive assay
Methods
0.000
description
2
239000003184
complementary RNA
Substances
0.000
description
2
238000004590
computer program
Methods
0.000
description
2
230000001276
controlling effect
Effects
0.000
description
2
230000002596
correlated effect
Effects
0.000
description
2
230000008878
coupling
Effects
0.000
description
2
238000010168
coupling process
Methods
0.000
description
2
238000005859
coupling reaction
Methods
0.000
description
2
OPTASPLRGRRNAP-UHFFFAOYSA-N
cytosine
Chemical compound
NC=1C=CNC(=O)N=1
OPTASPLRGRRNAP-UHFFFAOYSA-N
0.000
description
2
230000002950
deficient
Effects
0.000
description
2
230000003111
delayed effect
Effects
0.000
description
2
238000002716
delivery method
Methods
0.000
description
2
239000005547
deoxyribonucleotide
Substances
0.000
description
2
125000002637
deoxyribonucleotide group
Chemical group
0.000
description
2
238000013461
design
Methods
0.000
description
2
235000014113
dietary fatty acids
Nutrition
0.000
description
2
238000009792
diffusion process
Methods
0.000
description
2
239000000539
dimer
Substances
0.000
description
2
238000009826
distribution
Methods
0.000
description
2
238000007876
drug discovery
Methods
0.000
description
2
208000010118
dystonia
Diseases
0.000
description
2
238000004520
electroporation
Methods
0.000
description
2
230000002616
endonucleolytic effect
Effects
0.000
description
2
108700004025
env Genes
Proteins
0.000
description
2
239000002532
enzyme inhibitor
Substances
0.000
description
2
229960000403
etanercept
Drugs
0.000
description
2
210000003527
eukaryotic cell
Anatomy
0.000
description
2
238000002474
experimental method
Methods
0.000
description
2
238000010195
expression analysis
Methods
0.000
description
2
229930195729
fatty acid
Natural products
0.000
description
2
239000000194
fatty acid
Substances
0.000
description
2
150000004665
fatty acids
Chemical class
0.000
description
2
230000004720
fertilization
Effects
0.000
description
2
230000004907
flux
Effects
0.000
description
2
230000002538
fungal effect
Effects
0.000
description
2
229960003692
gamma aminobutyric acid
Drugs
0.000
description
2
210000001035
gastrointestinal tract
Anatomy
0.000
description
2
239000000499
gel
Substances
0.000
description
2
238000012226
gene silencing method
Methods
0.000
description
2
102000054767
gene variant
Human genes
0.000
description
2
208000005594
glucose-galactose malabsorption
Diseases
0.000
description
2
RWSXRVCMGQZWBV-WDSKDSINSA-N
glutathione
Chemical compound
OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O
RWSXRVCMGQZWBV-WDSKDSINSA-N
0.000
description
2
208000007345
glycogen storage disease
Diseases
0.000
description
2
201000004541
glycogen storage disease I
Diseases
0.000
description
2
201000004502
glycogen storage disease II
Diseases
0.000
description
2
230000012010
growth
Effects
0.000
description
2
102000006638
guanylate kinase
Human genes
0.000
description
2
210000002216
heart
Anatomy
0.000
description
2
229940088597
hormone
Drugs
0.000
description
2
239000005556
hormone
Substances
0.000
description
2
JYGXADMDTFJGBT-VWUMJDOOSA-N
hydrocortisone
Chemical compound
O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1
JYGXADMDTFJGBT-VWUMJDOOSA-N
0.000
description
2
229910052739
hydrogen
Inorganic materials
0.000
description
2
239000001257
hydrogen
Substances
0.000
description
2
230000002218
hypoglycaemic effect
Effects
0.000
description
2
230000002519
immonomodulatory effect
Effects
0.000
description
2
230000036737
immune function
Effects
0.000
description
2
210000000987
immune system
Anatomy
0.000
description
2
208000026278
immune system disease
Diseases
0.000
description
2
229940027941
immunoglobulin g
Drugs
0.000
description
2
230000002779
inactivation
Effects
0.000
description
2
208000023692
inborn mitochondrial myopathy
Diseases
0.000
description
2
201000008319
inclusion body myositis
Diseases
0.000
description
2
230000002458
infectious effect
Effects
0.000
description
2
208000015626
infectious myositis
Diseases
0.000
description
2
230000004941
influx
Effects
0.000
description
2
230000002401
inhibitory effect
Effects
0.000
description
2
208000014674
injury
Diseases
0.000
description
2
229940125396
insulin
Drugs
0.000
description
2
230000002452
interceptive effect
Effects
0.000
description
2
230000000968
intestinal effect
Effects
0.000
description
2
210000000936
intestine
Anatomy
0.000
description
2
150000002576
ketones
Chemical class
0.000
description
2
229940116871
l-lactate
Drugs
0.000
description
2
210000000265
leukocyte
Anatomy
0.000
description
2
150000002632
lipids
Chemical class
0.000
description
2
239000007788
liquid
Substances
0.000
description
2
208000004731
long QT syndrome
Diseases
0.000
description
2
210000004072
lung
Anatomy
0.000
description
2
210000004698
lymphocyte
Anatomy
0.000
description
2
239000006249
magnetic particle
Substances
0.000
description
2
102000003888
major urinary proteins
Human genes
0.000
description
2
108090000280
major urinary proteins
Proteins
0.000
description
2
201000007004
malignant hyperthermia
Diseases
0.000
description
2
238000013507
mapping
Methods
0.000
description
2
230000002503
metabolic effect
Effects
0.000
description
2
230000004060
metabolic process
Effects
0.000
description
2
230000009401
metastasis
Effects
0.000
description
2
206010061289
metastatic neoplasm
Diseases
0.000
description
2
238000000520
microinjection
Methods
0.000
description
2
VKHAHZOOUSRJNA-GCNJZUOMSA-N
mifepristone
Chemical compound
C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1
VKHAHZOOUSRJNA-GCNJZUOMSA-N
0.000
description
2
235000013336
milk
Nutrition
0.000
description
2
239000008267
milk
Substances
0.000
description
2
210000004080
milk
Anatomy
0.000
description
2
230000002438
mitochondrial effect
Effects
0.000
description
2
238000010369
molecular cloning
Methods
0.000
description
2
238000010172
mouse model
Methods
0.000
description
2
210000000663
muscle cell
Anatomy
0.000
description
2
208000010125
myocardial infarction
Diseases
0.000
description
2
208000018389
neoplasm of cerebral hemisphere
Diseases
0.000
description
2
230000001537
neural effect
Effects
0.000
description
2
230000004770
neurodegeneration
Effects
0.000
description
2
201000004931
neurofibromatosis
Diseases
0.000
description
2
230000003957
neurotransmitter release
Effects
0.000
description
2
QJGQUHMNIGDVPM-UHFFFAOYSA-N
nitrogen group
Chemical group
[N]
QJGQUHMNIGDVPM-UHFFFAOYSA-N
0.000
description
2
208000002154
non-small cell lung carcinoma
Diseases
0.000
description
2
210000001672
ovary
Anatomy
0.000
description
2
230000036407
pain
Effects
0.000
description
2
210000000496
pancreas
Anatomy
0.000
description
2
230000036961
partial effect
Effects
0.000
description
2
239000002245
particle
Substances
0.000
description
2
230000008506
pathogenesis
Effects
0.000
description
2
230000007170
pathology
Effects
0.000
description
2
208000029308
periodic paralysis
Diseases
0.000
description
2
230000000144
pharmacologic effect
Effects
0.000
description
2
235000021317
phosphate
Nutrition
0.000
description
2
230000004481
post-translational protein modification
Effects
0.000
description
2
230000001323
posttranslational effect
Effects
0.000
description
2
239000011591
potassium
Substances
0.000
description
2
229910052700
potassium
Inorganic materials
0.000
description
2
229910001414
potassium ion
Inorganic materials
0.000
description
2
230000003389
potentiating effect
Effects
0.000
description
2
238000004393
prognosis
Methods
0.000
description
2
230000001902
propagating effect
Effects
0.000
description
2
150000003180
prostaglandins
Chemical class
0.000
description
2
108020001580
protein domains
Proteins
0.000
description
2
108060006633
protein kinase
Proteins
0.000
description
2
230000009822
protein phosphorylation
Effects
0.000
description
2
238000001243
protein synthesis
Methods
0.000
description
2
230000006337
proteolytic cleavage
Effects
0.000
description
2
208000007750
pseudohypoaldosteronism
Diseases
0.000
description
2
208000015476
pseudohypoaldosteronism type 1
Diseases
0.000
description
2
238000005215
recombination
Methods
0.000
description
2
238000011084
recovery
Methods
0.000
description
2
230000036390
resting membrane potential
Effects
0.000
description
2
230000000717
retained effect
Effects
0.000
description
2
206010039073
rheumatoid arthritis
Diseases
0.000
description
2
201000000980
schizophrenia
Diseases
0.000
description
2
208000012672
seasonal affective disease
Diseases
0.000
description
2
QZAYGJVTTNCVMB-UHFFFAOYSA-N
serotonin
Chemical compound
C1=C(O)C=C2C(CCN)=CNC2=C1
QZAYGJVTTNCVMB-UHFFFAOYSA-N
0.000
description
2
230000019491
signal transduction
Effects
0.000
description
2
208000000587
small cell lung carcinoma
Diseases
0.000
description
2
239000007790
solid phase
Substances
0.000
description
2
210000000130
stem cell
Anatomy
0.000
description
2
230000035882
stress
Effects
0.000
description
2
208000024891
symptom
Diseases
0.000
description
2
230000005062
synaptic transmission
Effects
0.000
description
2
229940037128
systemic glucocorticoids
Drugs
0.000
description
2
230000008685
targeting
Effects
0.000
description
2
229940124597
therapeutic agent
Drugs
0.000
description
2
108060008226
thioredoxin
Proteins
0.000
description
2
231100000399
thyrotoxic
Toxicity
0.000
description
2
230000001897
thyrotoxic effect
Effects
0.000
description
2
231100000331
toxic
Toxicity
0.000
description
2
230000002588
toxic effect
Effects
0.000
description
2
230000014621
translational initiation
Effects
0.000
description
2
230000008733
trauma
Effects
0.000
description
2
230000010415
tropism
Effects
0.000
description
2
102000003390
tumor necrosis factor
Human genes
0.000
description
2
208000029729
tumor suppressor gene on chromosome 11
Diseases
0.000
description
2
241001515965
unidentified phage
Species
0.000
description
2
238000011144
upstream manufacturing
Methods
0.000
description
2
VBEQCZHXXJYVRD-GACYYNSASA-N
uroanthelone
Chemical compound
C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1
VBEQCZHXXJYVRD-GACYYNSASA-N
0.000
description
2
239000011782
vitamin
Substances
0.000
description
2
235000013343
vitamin
Nutrition
0.000
description
2
229940088594
vitamin
Drugs
0.000
description
2
229930003231
vitamin
Natural products
0.000
description
2
XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances
O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
2
OGNSCSPNOLGXSM-UHFFFAOYSA-N
(+/-)-DABA
Natural products
NCCC(N)C(O)=O
OGNSCSPNOLGXSM-UHFFFAOYSA-N
0.000
description
1
VLPIATFUUWWMKC-SNVBAGLBSA-N
(2r)-1-(2,6-dimethylphenoxy)propan-2-amine
Chemical compound
C[C@@H](N)COC1=C(C)C=CC=C1C
VLPIATFUUWWMKC-SNVBAGLBSA-N
0.000
description
1
ASWBNKHCZGQVJV-UHFFFAOYSA-N
(3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
Chemical compound
CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C
ASWBNKHCZGQVJV-UHFFFAOYSA-N
0.000
description
1
JVTAAEKCZFNVCJ-UWTATZPHSA-M
(R)-lactate
Chemical compound
C[C@@H](O)C([O-])=O
JVTAAEKCZFNVCJ-UWTATZPHSA-M
0.000
description
1
GHOKWGTUZJEAQD-ZETCQYMHSA-M
(R)-pantothenate
Chemical compound
OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O
GHOKWGTUZJEAQD-ZETCQYMHSA-M
0.000
description
1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N
100676-05-9
Natural products
OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N
0.000
description
1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N
13-cis retinol
Natural products
OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C
FPIPGXGPPPQFEQ-UHFFFAOYSA-N
0.000
description
1
UFBJCMHMOXMLKC-UHFFFAOYSA-N
2,4-dinitrophenol
Chemical compound
OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O
UFBJCMHMOXMLKC-UHFFFAOYSA-N
0.000
description
1
PFCLMNDDPTZJHQ-XLPZGREQSA-N
2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one
Chemical compound
C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1
PFCLMNDDPTZJHQ-XLPZGREQSA-N
0.000
description
1
KPGXRSRHYNQIFN-UHFFFAOYSA-N
2-oxoglutaric acid
Chemical compound
OC(=O)CCC(=O)C(O)=O
KPGXRSRHYNQIFN-UHFFFAOYSA-N
0.000
description
1
WHBMMWSBFZVSSR-UHFFFAOYSA-N
3-hydroxybutyric acid
Chemical compound
CC(O)CC(O)=O
WHBMMWSBFZVSSR-UHFFFAOYSA-N
0.000
description
1
LRSASMSXMSNRBT-UHFFFAOYSA-N
5-methylcytosine
Chemical compound
CC1=CNC(=O)N=C1N
LRSASMSXMSNRBT-UHFFFAOYSA-N
0.000
description
1
STQGQHZAVUOBTE-UHFFFAOYSA-N
7-Cyan-hept-2t-en-4,6-diinsaeure
Natural products
C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1
STQGQHZAVUOBTE-UHFFFAOYSA-N
0.000
description
1
102000041092
ABC transporter family
Human genes
0.000
description
1
108091060858
ABC transporter family
Proteins
0.000
description
1
101710103970
ADP,ATP carrier protein
Proteins
0.000
description
1
230000002407
ATP formation
Effects
0.000
description
1
108050008780
ATP-binding cassette sub-family D member 1
Proteins
0.000
description
1
102100020973
ATP-binding cassette sub-family D member 3
Human genes
0.000
description
1
101710152924
ATP-binding cassette sub-family D member 3
Proteins
0.000
description
1
102100033056
ATP-sensitive inward rectifier potassium channel 1
Human genes
0.000
description
1
QTBSBXVTEAMEQO-UHFFFAOYSA-M
Acetate
Chemical compound
CC([O-])=O
QTBSBXVTEAMEQO-UHFFFAOYSA-M
0.000
description
1
102100022094
Acid-sensing ion channel 2
Human genes
0.000
description
1
208000010444
Acidosis
Diseases
0.000
description
1
206010069754
Acquired gene mutation
Diseases
0.000
description
1
108010085238
Actins
Proteins
0.000
description
1
206010048998
Acute phase reaction
Diseases
0.000
description
1
206010001052
Acute respiratory distress syndrome
Diseases
0.000
description
1
229930024421
Adenine
Natural products
0.000
description
1
GFFGJBXGBJISGV-UHFFFAOYSA-N
Adenine
Chemical compound
NC1=NC=NC2=C1N=CN2
GFFGJBXGBJISGV-UHFFFAOYSA-N
0.000
description
1
108010024223
Adenine phosphoribosyltransferase
Proteins
0.000
description
1
206010001541
Akinesia
Diseases
0.000
description
1
CXISPYVYMQWFLE-VKHMYHEASA-N
Ala-Gly
Chemical compound
C[C@H]([NH3+])C(=O)NCC([O-])=O
CXISPYVYMQWFLE-VKHMYHEASA-N
0.000
description
1
108010025188
Alcohol oxidase
Proteins
0.000
description
1
102100039338
Aminomethyltransferase, mitochondrial
Human genes
0.000
description
1
QGZKDVFQNNGYKY-UHFFFAOYSA-N
Ammonia
Chemical compound
N
QGZKDVFQNNGYKY-UHFFFAOYSA-N
0.000
description
1
108050001492
Ammonium transporters
Proteins
0.000
description
1
206010002198
Anaphylactic reaction
Diseases
0.000
description
1
206010002199
Anaphylactic shock
Diseases
0.000
description
1
206010002556
Ankylosing Spondylitis
Diseases
0.000
description
1
108090000663
Annexin A1
Proteins
0.000
description
1
102100040006
Annexin A1
Human genes
0.000
description
1
108020000948
Antisense Oligonucleotides
Proteins
0.000
description
1
102000009333
Apolipoprotein D
Human genes
0.000
description
1
102000004391
Aquaporin 6
Human genes
0.000
description
1
108090000977
Aquaporin 6
Proteins
0.000
description
1
BNODVYXZAAXSHW-IUCAKERBSA-N
Arg-His
Chemical compound
NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1
BNODVYXZAAXSHW-IUCAKERBSA-N
0.000
description
1
239000004475
Arginine
Substances
0.000
description
1
206010003210
Arteriosclerosis
Diseases
0.000
description
1
VGRHZPNRCLAHQA-IMJSIDKUSA-N
Asp-Asn
Chemical compound
OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O
VGRHZPNRCLAHQA-IMJSIDKUSA-N
0.000
description
1
DCXYFEDJOCDNAF-UHFFFAOYSA-N
Asparagine
Natural products
OC(=O)C(N)CC(N)=O
DCXYFEDJOCDNAF-UHFFFAOYSA-N
0.000
description
1
206010003591
Ataxia
Diseases
0.000
description
1
206010003594
Ataxia telangiectasia
Diseases
0.000
description
1
208000004300
Atrophic Gastritis
Diseases
0.000
description
1
208000023275
Autoimmune disease
Diseases
0.000
description
1
208000012219
Autonomic Nervous System disease
Diseases
0.000
description
1
108700040618
BRCA1 Genes
Proteins
0.000
description
1
102000052609
BRCA2
Human genes
0.000
description
1
108700010154
BRCA2 Genes
Proteins
0.000
description
1
208000035143
Bacterial infection
Diseases
0.000
description
1
208000023328
Basedow disease
Diseases
0.000
description
1
208000006373
Bell palsy
Diseases
0.000
description
1
OGBVRMYSNSKIEF-UHFFFAOYSA-N
Benzylphosphonic acid
Chemical class
OP(O)(=O)CC1=CC=CC=C1
OGBVRMYSNSKIEF-UHFFFAOYSA-N
0.000
description
1
208000020925
Bipolar disease
Diseases
0.000
description
1
102000004506
Blood Proteins
Human genes
0.000
description
1
108010017384
Blood Proteins
Proteins
0.000
description
1
241000283725
Bos
Species
0.000
description
1
101001008231
Bos taurus Beta-lactoglobulin
Proteins
0.000
description
1
101000800130
Bos taurus Thyroglobulin
Proteins
0.000
description
1
108091003079
Bovine Serum Albumin
Proteins
0.000
description
1
208000004020
Brain Abscess
Diseases
0.000
description
1
208000014644
Brain disease
Diseases
0.000
description
1
206010006220
Breast cyst
Diseases
0.000
description
1
206010006811
Bursitis
Diseases
0.000
description
1
238000011740
C57BL/6 mouse
Methods
0.000
description
1
108700037257
CBS domains
Proteins
0.000
description
1
102000047411
CBS domains
Human genes
0.000
description
1
101000611262
Caenorhabditis elegans Probable protein phosphatase 2C T23F11.1
Proteins
0.000
description
1
101100113656
Caenorhabditis elegans clc-5 gene
Proteins
0.000
description
1
101100152433
Caenorhabditis elegans tat-1 gene
Proteins
0.000
description
1
101100314454
Caenorhabditis elegans tra-1 gene
Proteins
0.000
description
1
102000005701
Calcium-Binding Proteins
Human genes
0.000
description
1
108010045403
Calcium-Binding Proteins
Proteins
0.000
description
1
102100023073
Calcium-activated potassium channel subunit alpha-1
Human genes
0.000
description
1
241000282836
Camelus dromedarius
Species
0.000
description
1
241000173351
Camvirus
Species
0.000
description
1
241000222122
Candida albicans
Species
0.000
description
1
241000283707
Capra
Species
0.000
description
1
208000020446
Cardiac disease
Diseases
0.000
description
1
102000052052
Casein Kinase II
Human genes
0.000
description
1
108010010919
Casein Kinase II
Proteins
0.000
description
1
208000002177
Cataract
Diseases
0.000
description
1
241000701489
Cauliflower mosaic virus
Species
0.000
description
1
101150047856
Cav2 gene
Proteins
0.000
description
1
101150110214
Cav3 gene
Proteins
0.000
description
1
208000015374
Central core disease
Diseases
0.000
description
1
208000010693
Charcot-Marie-Tooth Disease
Diseases
0.000
description
1
102000019034
Chemokines
Human genes
0.000
description
1
108010012236
Chemokines
Proteins
0.000
description
1
239000005496
Chlorsulfuron
Substances
0.000
description
1
VYZAMTAEIAYCRO-UHFFFAOYSA-N
Chromium
Chemical compound
[Cr]
VYZAMTAEIAYCRO-UHFFFAOYSA-N
0.000
description
1
208000006545
Chronic Obstructive Pulmonary Disease
Diseases
0.000
description
1
KRKNYBCHXYNGOX-UHFFFAOYSA-K
Citrate
Chemical compound
[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O
KRKNYBCHXYNGOX-UHFFFAOYSA-K
0.000
description
1
206010009900
Colitis ulcerative
Diseases
0.000
description
1
208000035473
Communicable disease
Diseases
0.000
description
1
108020004394
Complementary RNA
Proteins
0.000
description
1
208000011990
Corticobasal Degeneration
Diseases
0.000
description
1
241000186216
Corynebacterium
Species
0.000
description
1
208000019736
Cranial nerve disease
Diseases
0.000
description
1
208000020406
Creutzfeldt Jacob disease
Diseases
0.000
description
1
208000003407
Creutzfeldt-Jakob Syndrome
Diseases
0.000
description
1
208000010859
Creutzfeldt-Jakob disease
Diseases
0.000
description
1
241000699800
Cricetinae
Species
0.000
description
1
208000011231
Crohn disease
Diseases
0.000
description
1
239000004971
Cross linker
Substances
0.000
description
1
208000014311
Cushing syndrome
Diseases
0.000
description
1
241000192700
Cyanobacteria
Species
0.000
description
1
101710095468
Cyclase
Proteins
0.000
description
1
102000008130
Cyclic AMP-Dependent Protein Kinases
Human genes
0.000
description
1
108010049894
Cyclic AMP-Dependent Protein Kinases
Proteins
0.000
description
1
108010079245
Cystic Fibrosis Transmembrane Conductance Regulator
Proteins
0.000
description
1
102100023419
Cystic fibrosis transmembrane conductance regulator
Human genes
0.000
description
1
102000004127
Cytokines
Human genes
0.000
description
1
108090000695
Cytokines
Proteins
0.000
description
1
IGXWBGJHJZYPQS-SSDOTTSWSA-N
D-Luciferin
Chemical compound
OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1
IGXWBGJHJZYPQS-SSDOTTSWSA-N
0.000
description
1
WQZGKKKJIJFFOK-QTVWNMPRSA-N
D-mannopyranose
Chemical compound
OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O
WQZGKKKJIJFFOK-QTVWNMPRSA-N
0.000
description
1
101150074155
DHFR gene
Proteins
0.000
description
1
230000004568
DNA-binding
Effects
0.000
description
1
108010014303
DNA-directed DNA polymerase
Proteins
0.000
description
1
102000016928
DNA-directed DNA polymerase
Human genes
0.000
description
1
206010011878
Deafness
Diseases
0.000
description
1
206010011882
Deafness congenital
Diseases
0.000
description
1
CYCGRDQQIOGCKX-UHFFFAOYSA-N
Dehydro-luciferin
Natural products
OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1
CYCGRDQQIOGCKX-UHFFFAOYSA-N
0.000
description
1
208000016192
Demyelinating disease
Diseases
0.000
description
1
241000702421
Dependoparvovirus
Species
0.000
description
1
206010012438
Dermatitis atopic
Diseases
0.000
description
1
206010012442
Dermatitis contact
Diseases
0.000
description
1
206010012559
Developmental delay
Diseases
0.000
description
1
208000012239
Developmental disease
Diseases
0.000
description
1
102000016862
Dicarboxylic Acid Transporters
Human genes
0.000
description
1
108010092943
Dicarboxylic Acid Transporters
Proteins
0.000
description
1
201000010374
Down Syndrome
Diseases
0.000
description
1
206010014561
Emphysema
Diseases
0.000
description
1
208000032274
Encephalopathy
Diseases
0.000
description
1
102100038132
Endogenous retrovirus group K member 6 Pro protein
Human genes
0.000
description
1
102100031780
Endonuclease
Human genes
0.000
description
1
102000004533
Endonucleases
Human genes
0.000
description
1
241000701867
Enterobacteria phage T7
Species
0.000
description
1
101710091045
Envelope protein
Proteins
0.000
description
1
206010014950
Eosinophilia
Diseases
0.000
description
1
102400001368
Epidermal growth factor
Human genes
0.000
description
1
101800003838
Epidermal growth factor
Proteins
0.000
description
1
108010003333
Equus caballus Equ c1 allergen
Proteins
0.000
description
1
206010015226
Erythema nodosum
Diseases
0.000
description
1
206010015251
Erythroblastosis foetalis
Diseases
0.000
description
1
208000032027
Essential Thrombocythemia
Diseases
0.000
description
1
241000206602
Eukaryota
Species
0.000
description
1
108091029865
Exogenous DNA
Proteins
0.000
description
1
108060002716
Exonuclease
Proteins
0.000
description
1
108091060211
Expressed sequence tag
Proteins
0.000
description
1
206010061846
Extradural abscess
Diseases
0.000
description
1
108010027279
Facilitative Glucose Transport Proteins
Proteins
0.000
description
1
108010054218
Factor VIII
Proteins
0.000
description
1
102000001690
Factor VIII
Human genes
0.000
description
1
201000003542
Factor VIII deficiency
Diseases
0.000
description
1
208000001441
Familial Periodic Paralyses
Diseases
0.000
description
1
201000006328
Fanconi syndrome
Diseases
0.000
description
1
208000037251
Fanconi-Bickel syndrome
Diseases
0.000
description
1
241000282326
Felis catus
Species
0.000
description
1
208000000571
Fibrocystic breast disease
Diseases
0.000
description
1
206010016654
Fibrosis
Diseases
0.000
description
1
BJGNCJDXODQBOB-UHFFFAOYSA-N
Fivefly Luciferin
Natural products
OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1
BJGNCJDXODQBOB-UHFFFAOYSA-N
0.000
description
1
102000005698
Frizzled receptors
Human genes
0.000
description
1
108010045438
Frizzled receptors
Proteins
0.000
description
1
229930091371
Fructose
Natural products
0.000
description
1
RFSUNEUAIZKAJO-ARQDHWQXSA-N
Fructose
Chemical compound
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O
RFSUNEUAIZKAJO-ARQDHWQXSA-N
0.000
description
1
239000005715
Fructose
Substances
0.000
description
1
206010017533
Fungal infection
Diseases
0.000
description
1
241000233866
Fungi
Species
0.000
description
1
102000034355
G beta-gamma complex
Human genes
0.000
description
1
108091006102
G beta-gamma complex
Proteins
0.000
description
1
108091006027
G proteins
Proteins
0.000
description
1
108090000045
G-Protein-Coupled Receptors
Proteins
0.000
description
1
102000003688
G-Protein-Coupled Receptors
Human genes
0.000
description
1
102000030782
GTP binding
Human genes
0.000
description
1
108091000058
GTP-Binding
Proteins
0.000
description
1
208000036495
Gastritis atrophic
Diseases
0.000
description
1
230000010558
Gene Alterations
Effects
0.000
description
1
208000034826
Genetic Predisposition to Disease
Diseases
0.000
description
1
208000003736
Gerstmann-Straussler-Scheinker Disease
Diseases
0.000
description
1
206010072075
Gerstmann-Straussler-Scheinker syndrome
Diseases
0.000
description
1
206010018364
Glomerulonephritis
Diseases
0.000
description
1
SAEBUDRWKUXLOM-ACZMJKKPSA-N
Glu-Cys-Ala
Chemical compound
OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O
SAEBUDRWKUXLOM-ACZMJKKPSA-N
0.000
description
1
102000053187
Glucuronidase
Human genes
0.000
description
1
108010060309
Glucuronidase
Proteins
0.000
description
1
108010024636
Glutathione
Proteins
0.000
description
1
102000003886
Glycoproteins
Human genes
0.000
description
1
108090000288
Glycoproteins
Proteins
0.000
description
1
VPZXBVLAVMBEQI-VKHMYHEASA-N
Glycyl-alanine
Chemical compound
OC(=O)[C@H](C)NC(=O)CN
VPZXBVLAVMBEQI-VKHMYHEASA-N
0.000
description
1
206010018498
Goitre
Diseases
0.000
description
1
208000024869
Goodpasture syndrome
Diseases
0.000
description
1
201000005569
Gout
Diseases
0.000
description
1
108010043121
Green Fluorescent Proteins
Proteins
0.000
description
1
102000004144
Green Fluorescent Proteins
Human genes
0.000
description
1
206010019196
Head injury
Diseases
0.000
description
1
206010061201
Helminthic infection
Diseases
0.000
description
1
102000001554
Hemoglobins
Human genes
0.000
description
1
108010054147
Hemoglobins
Proteins
0.000
description
1
208000035186
Hemolytic Autoimmune Anemia
Diseases
0.000
description
1
208000031220
Hemophilia
Diseases
0.000
description
1
208000005176
Hepatitis C
Diseases
0.000
description
1
208000002972
Hepatolenticular Degeneration
Diseases
0.000
description
1
102100036284
Hepcidin
Human genes
0.000
description
1
208000033640
Hereditary breast cancer
Diseases
0.000
description
1
208000017095
Hereditary nonpolyposis colon cancer
Diseases
0.000
description
1
241000238631
Hexapoda
Species
0.000
description
1
WSDOHRLQDGAOGU-BQBZGAKWSA-N
His-Asn
Chemical compound
NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1
WSDOHRLQDGAOGU-BQBZGAKWSA-N
0.000
description
1
108010072039
Histidine kinase
Proteins
0.000
description
1
101000944272
Homo sapiens ATP-sensitive inward rectifier potassium channel 1
Proteins
0.000
description
1
101001021253
Homo sapiens Hepcidin
Proteins
0.000
description
1
101001049841
Homo sapiens Potassium channel subfamily K member 1
Proteins
0.000
description
1
241000700588
Human alphaherpesvirus 1
Species
0.000
description
1
101001042049
Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22
Proteins
0.000
description
1
101000999690
Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22
Proteins
0.000
description
1
208000023105
Huntington disease
Diseases
0.000
description
1
UFHFLCQGNIYNRP-UHFFFAOYSA-N
Hydrogen
Chemical compound
[H][H]
UFHFLCQGNIYNRP-UHFFFAOYSA-N
0.000
description
1
208000007599
Hyperkalemic periodic paralysis
Diseases
0.000
description
1
208000000563
Hyperlipoproteinemia Type II
Diseases
0.000
description
1
206010020850
Hyperthyroidism
Diseases
0.000
description
1
101150027427
ICP4 gene
Proteins
0.000
description
1
108010021625
Immunoglobulin Fragments
Proteins
0.000
description
1
102000008394
Immunoglobulin Fragments
Human genes
0.000
description
1
102000017727
Immunoglobulin Variable Region
Human genes
0.000
description
1
108010067060
Immunoglobulin Variable Region
Proteins
0.000
description
1
108020005350
Initiator Codon
Proteins
0.000
description
1
229930010555
Inosine
Natural products
0.000
description
1
UGQMRVRMYYASKQ-KQYNXXCUSA-N
Inosine
Chemical compound
O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1
UGQMRVRMYYASKQ-KQYNXXCUSA-N
0.000
description
1
102100034349
Integrase
Human genes
0.000
description
1
102000001702
Intracellular Signaling Peptides and Proteins
Human genes
0.000
description
1
108010068964
Intracellular Signaling Peptides and Proteins
Proteins
0.000
description
1
108091092195
Intron
Proteins
0.000
description
1
208000032382
Ischaemic stroke
Diseases
0.000
description
1
108010025815
Kanamycin Kinase
Proteins
0.000
description
1
206010048804
Kearns-Sayre syndrome
Diseases
0.000
description
1
208000000913
Kidney Calculi
Diseases
0.000
description
1
241000235058
Komagataella pastoris
Species
0.000
description
1
QNAYBMKLOCPYGJ-REOHCLBHSA-N
L-alanine
Chemical compound
C[C@H](N)C(O)=O
QNAYBMKLOCPYGJ-REOHCLBHSA-N
0.000
description
1
CKLJMWTZIZZHCS-REOHCLBHSA-N
L-aspartic acid
Chemical compound
OC(=O)[C@@H](N)CC(O)=O
CKLJMWTZIZZHCS-REOHCLBHSA-N
0.000
description
1
ZDXPYRJPNDTMRX-VKHMYHEASA-N
L-glutamine
Chemical compound
OC(=O)[C@@H](N)CCC(N)=O
ZDXPYRJPNDTMRX-VKHMYHEASA-N
0.000
description
1
AGPKZVBTJJNPAG-WHFBIAKZSA-N
L-isoleucine
Chemical compound
CC[C@H](C)[C@H](N)C(O)=O
AGPKZVBTJJNPAG-WHFBIAKZSA-N
0.000
description
1
FFEARJCKVFRZRR-BYPYZUCNSA-N
L-methionine
Chemical compound
CSCC[C@H](N)C(O)=O
FFEARJCKVFRZRR-BYPYZUCNSA-N
0.000
description
1
FBOZXECLQNJBKD-ZDUSSCGKSA-N
L-methotrexate
Chemical compound
C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1
FBOZXECLQNJBKD-ZDUSSCGKSA-N
0.000
description
1
OUYCCCASQSFEME-QMMMGPOBSA-N
L-tyrosine
Chemical compound
OC(=O)[C@@H](N)CC1=CC=C(O)C=C1
OUYCCCASQSFEME-QMMMGPOBSA-N
0.000
description
1
KZSNJWFQEVHDMF-BYPYZUCNSA-N
L-valine
Chemical compound
CC(C)[C@H](N)C(O)=O
KZSNJWFQEVHDMF-BYPYZUCNSA-N
0.000
description
1
108010092555
Large-Conductance Calcium-Activated Potassium Channels
Proteins
0.000
description
1
101000688229
Leishmania chagasi Protein phosphatase 2C
Proteins
0.000
description
1
108700005090
Lethal Genes
Proteins
0.000
description
1
ROHFNLRQFUQHCH-UHFFFAOYSA-N
Leucine
Natural products
CC(C)CC(N)C(O)=O
ROHFNLRQFUQHCH-UHFFFAOYSA-N
0.000
description
1
NNJVILVZKWQKPM-UHFFFAOYSA-N
Lidocaine
Chemical compound
CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
NNJVILVZKWQKPM-UHFFFAOYSA-N
0.000
description
1
239000000232
Lipid Bilayer
Substances
0.000
description
1
108010028921
Lipopeptides
Proteins
0.000
description
1
102100024640
Low-density lipoprotein receptor
Human genes
0.000
description
1
108060001084
Luciferase
Proteins
0.000
description
1
239000005089
Luciferase
Substances
0.000
description
1
DDWFXDSYGUXRAY-UHFFFAOYSA-N
Luciferin
Natural products
CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C
DDWFXDSYGUXRAY-UHFFFAOYSA-N
0.000
description
1
102000008072
Lymphokines
Human genes
0.000
description
1
108010074338
Lymphokines
Proteins
0.000
description
1
206010025323
Lymphomas
Diseases
0.000
description
1
206010025327
Lymphopenia
Diseases
0.000
description
1
NPBGTPKLVJEOBE-IUCAKERBSA-N
Lys-Arg
Chemical compound
NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N
NPBGTPKLVJEOBE-IUCAKERBSA-N
0.000
description
1
102000011364
Major intrinsic proteins
Human genes
0.000
description
1
108050001696
Major intrinsic proteins
Proteins
0.000
description
1
GUBGYTABKSRVRQ-PICCSMPSSA-N
Maltose
Natural products
O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O
GUBGYTABKSRVRQ-PICCSMPSSA-N
0.000
description
1
208000003289
Meconium Ileus
Diseases
0.000
description
1
102000012750
Membrane Glycoproteins
Human genes
0.000
description
1
108010090054
Membrane Glycoproteins
Proteins
0.000
description
1
102000018697
Membrane Proteins
Human genes
0.000
description
1
102000003939
Membrane transport proteins
Human genes
0.000
description
1
108090000301
Membrane transport proteins
Proteins
0.000
description
1
206010027202
Meningitis bacterial
Diseases
0.000
description
1
206010027260
Meningitis viral
Diseases
0.000
description
1
208000008948
Menkes Kinky Hair Syndrome
Diseases
0.000
description
1
208000012583
Menkes disease
Diseases
0.000
description
1
208000036626
Mental retardation
Diseases
0.000
description
1
206010068836
Metabolic myopathy
Diseases
0.000
description
1
101100261636
Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene
Proteins
0.000
description
1
208000032818
Microsatellite Instability
Diseases
0.000
description
1
208000019695
Migraine disease
Diseases
0.000
description
1
108050006262
Mitochondrial carrier proteins
Proteins
0.000
description
1
102000016647
Mitochondrial carrier proteins
Human genes
0.000
description
1
ZOKXTWBITQBERF-UHFFFAOYSA-N
Molybdenum
Chemical compound
[Mo]
ZOKXTWBITQBERF-UHFFFAOYSA-N
0.000
description
1
102000017298
Monocarboxylate transporters
Human genes
0.000
description
1
108050005244
Monocarboxylate transporters
Proteins
0.000
description
1
102000000562
Monocarboxylic Acid Transporters
Human genes
0.000
description
1
108010041817
Monocarboxylic Acid Transporters
Proteins
0.000
description
1
208000019022
Mood disease
Diseases
0.000
description
1
241000699660
Mus musculus
Species
0.000
description
1
208000031888
Mycoses
Diseases
0.000
description
1
208000003926
Myelitis
Diseases
0.000
description
1
206010028643
Myopathy endocrine
Diseases
0.000
description
1
208000023137
Myotoxicity
Diseases
0.000
description
1
108090000699
N-Type Calcium Channels
Proteins
0.000
description
1
102000004129
N-Type Calcium Channels
Human genes
0.000
description
1
108010079364
N-glycylalanine
Proteins
0.000
description
1
229910002651
NO3
Inorganic materials
0.000
description
1
208000000592
Nasal Polyps
Diseases
0.000
description
1
229930193140
Neomycin
Natural products
0.000
description
1
206010029148
Nephrolithiasis
Diseases
0.000
description
1
102000001584
Neurotransmitter-gated ion-channels
Human genes
0.000
description
1
108050009804
Neurotransmitter-gated ion-channels
Proteins
0.000
description
1
NHNBFGGVMKEFGY-UHFFFAOYSA-N
Nitrate
Chemical compound
[O-][N+]([O-])=O
NHNBFGGVMKEFGY-UHFFFAOYSA-N
0.000
description
1
102000007399
Nuclear hormone receptor
Human genes
0.000
description
1
101710163270
Nuclease
Proteins
0.000
description
1
208000008589
Obesity
Diseases
0.000
description
1
108020005187
Oligonucleotide Probes
Proteins
0.000
description
1
108700020796
Oncogene
Proteins
0.000
description
1
108010089503
Organic Anion Transporters
Proteins
0.000
description
1
102000007990
Organic Anion Transporters
Human genes
0.000
description
1
108091006764
Organic cation transporters
Proteins
0.000
description
1
208000001132
Osteoporosis
Diseases
0.000
description
1
208000007571
Ovarian Epithelial Carcinoma
Diseases
0.000
description
1
108090000854
Oxidoreductases
Proteins
0.000
description
1
102000004316
Oxidoreductases
Human genes
0.000
description
1
108700012358
P/Q-type calcium channel
Proteins
0.000
description
1
102000050761
P/Q-type calcium channel
Human genes
0.000
description
1
238000009004
PCR Kit
Methods
0.000
description
1
102000000470
PDZ domains
Human genes
0.000
description
1
108050008994
PDZ domains
Proteins
0.000
description
1
208000035467
Pancreatic insufficiency
Diseases
0.000
description
1
206010033645
Pancreatitis
Diseases
0.000
description
1
241000526686
Paracoccidioides brasiliensis
Species
0.000
description
1
208000030852
Parasitic disease
Diseases
0.000
description
1
208000000733
Paroxysmal Hemoglobinuria
Diseases
0.000
description
1
102000057297
Pepsin A
Human genes
0.000
description
1
108090000284
Pepsin A
Proteins
0.000
description
1
108091005804
Peptidases
Proteins
0.000
description
1
108010067902
Peptide Library
Proteins
0.000
description
1
229940083963
Peptide antagonist
Drugs
0.000
description
1
208000037581
Persistent Infection
Diseases
0.000
description
1
206010057249
Phagocytosis
Diseases
0.000
description
1
108091007643
Phosphate carriers
Proteins
0.000
description
1
102100036050
Phosphatidylinositol N-acetylglucosaminyltransferase subunit A
Human genes
0.000
description
1
108090000608
Phosphoric Monoester Hydrolases
Proteins
0.000
description
1
102000004160
Phosphoric Monoester Hydrolases
Human genes
0.000
description
1
108091000080
Phosphotransferase
Proteins
0.000
description
1
101100124346
Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene
Proteins
0.000
description
1
208000000609
Pick Disease of the Brain
Diseases
0.000
description
1
208000010067
Pituitary ACTH Hypersecretion
Diseases
0.000
description
1
208000020627
Pituitary-dependent Cushing syndrome
Diseases
0.000
description
1
206010035226
Plasma cell myeloma
Diseases
0.000
description
1
241000223960
Plasmodium falciparum
Species
0.000
description
1
241000881705
Porcine endogenous retrovirus
Species
0.000
description
1
102100023242
Potassium channel subfamily K member 1
Human genes
0.000
description
1
102100023204
Potassium channel subfamily K member 2
Human genes
0.000
description
1
ORNBQBCIOKFOEO-YQUGOWONSA-N
Pregnenolone
Natural products
O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1
ORNBQBCIOKFOEO-YQUGOWONSA-N
0.000
description
1
241000288906
Primates
Species
0.000
description
1
208000024777
Prion disease
Diseases
0.000
description
1
206010060862
Prostate cancer
Diseases
0.000
description
1
208000000236
Prostatic Neoplasms
Diseases
0.000
description
1
239000004365
Protease
Substances
0.000
description
1
102000003923
Protein Kinase C
Human genes
0.000
description
1
108090000315
Protein Kinase C
Proteins
0.000
description
1
108010076504
Protein Sorting Signals
Proteins
0.000
description
1
101710188315
Protein X
Proteins
0.000
description
1
102000004669
Protein-Lysine 6-Oxidase
Human genes
0.000
description
1
108010003894
Protein-Lysine 6-Oxidase
Proteins
0.000
description
1
108090000412
Protein-Tyrosine Kinases
Proteins
0.000
description
1
102000004022
Protein-Tyrosine Kinases
Human genes
0.000
description
1
206010037075
Protozoal infections
Diseases
0.000
description
1
208000006396
Pulmonary artery stenosis
Diseases
0.000
description
1
108020004518
RNA Probes
Proteins
0.000
description
1
108091008103
RNA aptamers
Proteins
0.000
description
1
239000003391
RNA probe
Substances
0.000
description
1
206010037779
Radiculopathy
Diseases
0.000
description
1
102000007056
Recombinant Fusion Proteins
Human genes
0.000
description
1
108010008281
Recombinant Fusion Proteins
Proteins
0.000
description
1
208000033464
Reiter syndrome
Diseases
0.000
description
1
208000026980
Renal tubular disease
Diseases
0.000
description
1
108091081062
Repeated sequence (DNA)
Proteins
0.000
description
1
108700008625
Reporter Genes
Proteins
0.000
description
1
208000013616
Respiratory Distress Syndrome
Diseases
0.000
description
1
208000007014
Retinitis pigmentosa
Diseases
0.000
description
1
108010003581
Ribulose-bisphosphate carboxylase
Proteins
0.000
description
1
102000013674
S-100
Human genes
0.000
description
1
108700021018
S100
Proteins
0.000
description
1
108010005173
SERPIN-B5
Proteins
0.000
description
1
108091006296
SLC2A1
Proteins
0.000
description
1
108091006299
SLC2A2
Proteins
0.000
description
1
108091006298
SLC2A3
Proteins
0.000
description
1
108091006300
SLC2A4
Proteins
0.000
description
1
108091006301
SLC2A5
Proteins
0.000
description
1
102000000583
SNARE Proteins
Human genes
0.000
description
1
108010041948
SNARE Proteins
Proteins
0.000
description
1
101001075014
Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Anion/proton exchange transporter GEF1
Proteins
0.000
description
1
101100221606
Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene
Proteins
0.000
description
1
208000036752
Schizophrenia, paranoid type
Diseases
0.000
description
1
241000235347
Schizosaccharomyces pombe
Species
0.000
description
1
206010039710
Scleroderma
Diseases
0.000
description
1
BUGBHKTXTAQXES-UHFFFAOYSA-N
Selenium
Chemical compound
[Se]
BUGBHKTXTAQXES-UHFFFAOYSA-N
0.000
description
1
108091081021
Sense strand
Proteins
0.000
description
1
MTCFGRXMJLQNBG-UHFFFAOYSA-N
Serine
Natural products
OCC(N)C(O)=O
MTCFGRXMJLQNBG-UHFFFAOYSA-N
0.000
description
1
102100030333
Serpin B5
Human genes
0.000
description
1
108020004682
Single-Stranded DNA
Proteins
0.000
description
1
208000021386
Sjogren Syndrome
Diseases
0.000
description
1
208000013738
Sleep Initiation and Maintenance disease
Diseases
0.000
description
1
102100023536
Solute carrier family 2, facilitated glucose transporter member 1
Human genes
0.000
description
1
102100023537
Solute carrier family 2, facilitated glucose transporter member 2
Human genes
0.000
description
1
102100022722
Solute carrier family 2, facilitated glucose transporter member 3
Human genes
0.000
description
1
102100033939
Solute carrier family 2, facilitated glucose transporter member 4
Human genes
0.000
description
1
102100022719
Solute carrier family 2, facilitated glucose transporter member 5
Human genes
0.000
description
1
108091027076
Spiegelmer
Proteins
0.000
description
1
208000029033
Spinal Cord disease
Diseases
0.000
description
1
208000010112
Spinocerebellar Degenerations
Diseases
0.000
description
1
229920002472
Starch
Polymers
0.000
description
1
229930182558
Sterol
Natural products
0.000
description
1
208000006011
Stroke
Diseases
0.000
description
1
206010042265
Sturge-Weber Syndrome
Diseases
0.000
description
1
201000000002
Subdural Empyema
Diseases
0.000
description
1
QAOWNCQODCNURD-UHFFFAOYSA-L
Sulfate
Chemical compound
[O-]S([O-])(=O)=O
QAOWNCQODCNURD-UHFFFAOYSA-L
0.000
description
1
102000019197
Superoxide Dismutase
Human genes
0.000
description
1
108010012715
Superoxide dismutase
Proteins
0.000
description
1
201000009594
Systemic Scleroderma
Diseases
0.000
description
1
206010042953
Systemic sclerosis
Diseases
0.000
description
1
230000006044
T cell activation
Effects
0.000
description
1
102000003691
T-Type Calcium Channels
Human genes
0.000
description
1
108090000030
T-Type Calcium Channels
Proteins
0.000
description
1
101150011263
Tap2 gene
Proteins
0.000
description
1
108010006785
Taq Polymerase
Proteins
0.000
description
1
108020005038
Terminator Codon
Proteins
0.000
description
1
239000004098
Tetracycline
Substances
0.000
description
1
RYYWUUFWQRZTIU-UHFFFAOYSA-N
Thiophosphoric acid
Chemical class
OP(O)(S)=O
RYYWUUFWQRZTIU-UHFFFAOYSA-N
0.000
description
1
208000035954
Thomsen and Becker disease
Diseases
0.000
description
1
AYFVYJQAPQTCCC-UHFFFAOYSA-N
Threonine
Natural products
CC(O)C(N)C(O)=O
AYFVYJQAPQTCCC-UHFFFAOYSA-N
0.000
description
1
239000004473
Threonine
Substances
0.000
description
1
206010043561
Thrombocytopenic purpura
Diseases
0.000
description
1
102000009843
Thyroglobulin
Human genes
0.000
description
1
108700009124
Transcription Initiation Site
Proteins
0.000
description
1
241000209140
Triticum
Species
0.000
description
1
235000021307
Triticum
Nutrition
0.000
description
1
IMMPMHKLUUZKAZ-WMZOPIPTSA-N
Trp-Phe
Chemical compound
C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1
IMMPMHKLUUZKAZ-WMZOPIPTSA-N
0.000
description
1
LWFWZRANSFAJDR-JSGCOSHPSA-N
Trp-Val
Chemical compound
C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1
LWFWZRANSFAJDR-JSGCOSHPSA-N
0.000
description
1
241000223109
Trypanosoma cruzi
Species
0.000
description
1
208000026911
Tuberous sclerosis complex
Diseases
0.000
description
1
206010045261
Type IIa hyperlipidaemia
Diseases
0.000
description
1
206010053613
Type IV hypersensitivity reaction
Diseases
0.000
description
1
AFWXOGHZEKARFH-ACRUOGEOSA-N
Tyr-Tyr-His
Chemical compound
C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1
AFWXOGHZEKARFH-ACRUOGEOSA-N
0.000
description
1
201000006704
Ulcerative Colitis
Diseases
0.000
description
1
102000037089
Uniporters
Human genes
0.000
description
1
108091006293
Uniporters
Proteins
0.000
description
1
206010046851
Uveitis
Diseases
0.000
description
1
208000036826
VIIth nerve paralysis
Diseases
0.000
description
1
102100026383
Vasopressin-neurophysin 2-copeptin
Human genes
0.000
description
1
102000003734
Voltage-Gated Potassium Channels
Human genes
0.000
description
1
108090000013
Voltage-Gated Potassium Channels
Proteins
0.000
description
1
IXKSXJFAGXLQOQ-XISFHERQSA-N
WHWLQLKPGQPMY
Chemical compound
C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1
IXKSXJFAGXLQOQ-XISFHERQSA-N
0.000
description
1
201000011032
Werner Syndrome
Diseases
0.000
description
1
208000018839
Wilson disease
Diseases
0.000
description
1
108700029631
X-Linked Genes
Proteins
0.000
description
1
208000028247
X-linked inheritance
Diseases
0.000
description
1
HCHKCACWOHOZIP-UHFFFAOYSA-N
Zinc
Chemical compound
[Zn]
HCHKCACWOHOZIP-UHFFFAOYSA-N
0.000
description
1
230000001133
acceleration
Effects
0.000
description
1
WDJHALXBUFZDSR-UHFFFAOYSA-M
acetoacetate
Chemical compound
CC(=O)CC([O-])=O
WDJHALXBUFZDSR-UHFFFAOYSA-M
0.000
description
1
229960004373
acetylcholine
Drugs
0.000
description
1
108020002494
acetyltransferase
Proteins
0.000
description
1
102000005421
acetyltransferase
Human genes
0.000
description
1
230000002378
acidificating effect
Effects
0.000
description
1
230000007950
acidosis
Effects
0.000
description
1
208000026545
acidosis disease
Diseases
0.000
description
1
208000017733
acquired polycythemia vera
Diseases
0.000
description
1
208000009621
actinic keratosis
Diseases
0.000
description
1
239000013543
active substance
Substances
0.000
description
1
230000004658
acute-phase response
Effects
0.000
description
1
125000002252
acyl group
Chemical group
0.000
description
1
230000010933
acylation
Effects
0.000
description
1
238000005917
acylation reaction
Methods
0.000
description
1
229960000643
adenine
Drugs
0.000
description
1
108060000200
adenylate cyclase
Proteins
0.000
description
1
102000030621
adenylate cyclase
Human genes
0.000
description
1
210000004100
adrenal gland
Anatomy
0.000
description
1
239000003463
adsorbent
Substances
0.000
description
1
208000011341
adult acute respiratory distress syndrome
Diseases
0.000
description
1
201000000028
adult respiratory distress syndrome
Diseases
0.000
description
1
230000002411
adverse
Effects
0.000
description
1
239000000443
aerosol
Substances
0.000
description
1
235000004279
alanine
Nutrition
0.000
description
1
108010047495
alanylglycine
Proteins
0.000
description
1
125000001931
aliphatic group
Chemical group
0.000
description
1
125000000217
alkyl group
Chemical group
0.000
description
1
208000026935
allergic disease
Diseases
0.000
description
1
230000000172
allergic effect
Effects
0.000
description
1
230000004075
alteration
Effects
0.000
description
1
WNROFYMDJYEPJX-UHFFFAOYSA-K
aluminium hydroxide
Chemical compound
[OH-].[OH-].[OH-].[Al+3]
WNROFYMDJYEPJX-UHFFFAOYSA-K
0.000
description
1
125000003277
amino group
Chemical group
0.000
description
1
229940126575
aminoglycoside
Drugs
0.000
description
1
206010002022
amyloidosis
Diseases
0.000
description
1
229940035676
analgesics
Drugs
0.000
description
1
208000007502
anemia
Diseases
0.000
description
1
239000000730
antalgic agent
Substances
0.000
description
1
239000004410
anthocyanin
Substances
0.000
description
1
229930002877
anthocyanin
Natural products
0.000
description
1
235000010208
anthocyanin
Nutrition
0.000
description
1
150000004636
anthocyanins
Chemical class
0.000
description
1
230000000947
anti-immunosuppressive effect
Effects
0.000
description
1
230000000340
anti-metabolite
Effects
0.000
description
1
239000002256
antimetabolite
Substances
0.000
description
1
229940100197
antimetabolite
Drugs
0.000
description
1
229940114079
arachidonic acid
Drugs
0.000
description
1
235000021342
arachidonic acid
Nutrition
0.000
description
1
ODKSFYDXXFIFQN-UHFFFAOYSA-N
arginine
Natural products
OC(=O)C(N)CCCNC(N)=N
ODKSFYDXXFIFQN-UHFFFAOYSA-N
0.000
description
1
208000011775
arteriosclerosis disease
Diseases
0.000
description
1
206010003246
arthritis
Diseases
0.000
description
1
210000001106
artificial yeast chromosome
Anatomy
0.000
description
1
235000009582
asparagine
Nutrition
0.000
description
1
229960001230
asparagine
Drugs
0.000
description
1
235000003704
aspartic acid
Nutrition
0.000
description
1
201000008937
atopic dermatitis
Diseases
0.000
description
1
208000010668
atopic eczema
Diseases
0.000
description
1
201000000448
autoimmune hemolytic anemia
Diseases
0.000
description
1
208000031375
autosomal dominant myotonia congenita
Diseases
0.000
description
1
210000003050
axon
Anatomy
0.000
description
1
208000022362
bacterial infectious disease
Diseases
0.000
description
1
201000009904
bacterial meningitis
Diseases
0.000
description
1
244000052616
bacterial pathogen
Species
0.000
description
1
108010058966
bacteriophage T7 induced DNA polymerase
Proteins
0.000
description
1
208000018300
basal ganglia disease
Diseases
0.000
description
1
239000011324
bead
Substances
0.000
description
1
OQFSQFPPLPISGP-UHFFFAOYSA-N
beta-carboxyaspartic acid
Natural products
OC(=O)C(N)C(C(O)=O)C(O)=O
OQFSQFPPLPISGP-UHFFFAOYSA-N
0.000
description
1
GUBGYTABKSRVRQ-QUYVBRFLSA-N
beta-maltose
Chemical compound
OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O
GUBGYTABKSRVRQ-QUYVBRFLSA-N
0.000
description
1
108010050063
beta-naphthylsulfonyl-R-(d-Pip)-Ada-Abu-DYEPIPEEA-(Cha)-(d-Glu)-OH-AcOH
Proteins
0.000
description
1
238000011953
bioanalysis
Methods
0.000
description
1
238000004166
bioassay
Methods
0.000
description
1
230000001851
biosynthetic effect
Effects
0.000
description
1
229960002685
biotin
Drugs
0.000
description
1
235000020958
biotin
Nutrition
0.000
description
1
239000011616
biotin
Substances
0.000
description
1
239000002981
blocking agent
Substances
0.000
description
1
230000017531
blood circulation
Effects
0.000
description
1
210000000988
bone and bone
Anatomy
0.000
description
1
230000014461
bone development
Effects
0.000
description
1
210000001185
bone marrow
Anatomy
0.000
description
1
229940098773
bovine serum albumin
Drugs
0.000
description
1
210000000069
breast epithelial cell
Anatomy
0.000
description
1
238000009395
breeding
Methods
0.000
description
1
230000001488
breeding effect
Effects
0.000
description
1
206010006451
bronchitis
Diseases
0.000
description
1
244000309464
bull
Species
0.000
description
1
230000009460
calcium influx
Effects
0.000
description
1
239000001506
calcium phosphate
Substances
0.000
description
1
229910000389
calcium phosphate
Inorganic materials
0.000
description
1
235000011010
calcium phosphates
Nutrition
0.000
description
1
230000028956
calcium-mediated signaling
Effects
0.000
description
1
238000004364
calculation method
Methods
0.000
description
1
229940095731
candida albicans
Drugs
0.000
description
1
229960002504
capsaicin
Drugs
0.000
description
1
235000017663
capsaicin
Nutrition
0.000
description
1
230000021523
carboxylation
Effects
0.000
description
1
238000006473
carboxylation reaction
Methods
0.000
description
1
230000015556
catabolic process
Effects
0.000
description
1
239000003054
catalyst
Substances
0.000
description
1
230000003197
catalytic effect
Effects
0.000
description
1
125000002091
cationic group
Chemical group
0.000
description
1
230000007910
cell fusion
Effects
0.000
description
1
230000010261
cell growth
Effects
0.000
description
1
230000022534
cell killing
Effects
0.000
description
1
230000006037
cell lysis
Effects
0.000
description
1
230000009087
cell motility
Effects
0.000
description
1
230000005859
cell recognition
Effects
0.000
description
1
230000029215
cell volume homeostasis
Effects
0.000
description
1
210000004671
cell-free system
Anatomy
0.000
description
1
229920002678
cellulose
Polymers
0.000
description
1
235000010980
cellulose
Nutrition
0.000
description
1
201000007303
central core myopathy
Diseases
0.000
description
1
208000015114
central nervous system disease
Diseases
0.000
description
1
206010008129
cerebral palsy
Diseases
0.000
description
1
208000026106
cerebrovascular disease
Diseases
0.000
description
1
210000003679
cervix uteri
Anatomy
0.000
description
1
239000013522
chelant
Substances
0.000
description
1
150000005829
chemical entities
Chemical class
0.000
description
1
239000005081
chemiluminescent agent
Substances
0.000
description
1
230000035605
chemotaxis
Effects
0.000
description
1
VJYIFXVZLXQVHO-UHFFFAOYSA-N
chlorsulfuron
Chemical compound
COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1
VJYIFXVZLXQVHO-UHFFFAOYSA-N
0.000
description
1
201000001352
cholecystitis
Diseases
0.000
description
1
235000012000
cholesterol
Nutrition
0.000
description
1
229910052804
chromium
Inorganic materials
0.000
description
1
239000011651
chromium
Substances
0.000
description
1
230000002759
chromosomal effect
Effects
0.000
description
1
208000016644
chronic atrophic gastritis
Diseases
0.000
description
1
DERZBLKQOCDDDZ-JLHYYAGUSA-N
cinnarizine
Chemical compound
C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1
DERZBLKQOCDDDZ-JLHYYAGUSA-N
0.000
description
1
230000004087
circulation
Effects
0.000
description
1
230000007882
cirrhosis
Effects
0.000
description
1
208000019425
cirrhosis of liver
Diseases
0.000
description
1
108010075600
citrate-binding transport protein
Proteins
0.000
description
1
239000013599
cloning vector
Substances
0.000
description
1
238000002648
combination therapy
Methods
0.000
description
1
230000009137
competitive binding
Effects
0.000
description
1
230000021615
conjugation
Effects
0.000
description
1
210000002808
connective tissue
Anatomy
0.000
description
1
208000010247
contact dermatitis
Diseases
0.000
description
1
230000008602
contraction
Effects
0.000
description
1
230000001054
cortical effect
Effects
0.000
description
1
239000003246
corticosteroid
Substances
0.000
description
1
229960001334
corticosteroids
Drugs
0.000
description
1
238000009402
cross-breeding
Methods
0.000
description
1
210000002726
cyst fluid
Anatomy
0.000
description
1
235000018417
cysteine
Nutrition
0.000
description
1
125000000151
cysteine group
Chemical class
N[C@@H](CS)C(=O)*
0.000
description
1
210000000805
cytoplasm
Anatomy
0.000
description
1
108091007930
cytoplasmic receptors
Proteins
0.000
description
1
229940104302
cytosine
Drugs
0.000
description
1
231100000433
cytotoxic
Toxicity
0.000
description
1
230000001472
cytotoxic effect
Effects
0.000
description
1
STQGQHZAVUOBTE-VGBVRHCVSA-N
daunorubicin
Chemical compound
O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
STQGQHZAVUOBTE-VGBVRHCVSA-N
0.000
description
1
229960000975
daunorubicin
Drugs
0.000
description
1
231100000895
deafness
Toxicity
0.000
description
1
230000007123
defense
Effects
0.000
description
1
238000006731
degradation reaction
Methods
0.000
description
1
210000004443
dendritic cell
Anatomy
0.000
description
1
230000002999
depolarising effect
Effects
0.000
description
1
239000003599
detergent
Substances
0.000
description
1
201000010064
diabetes insipidus
Diseases
0.000
description
1
235000005911
diet
Nutrition
0.000
description
1
230000037213
diet
Effects
0.000
description
1
230000004069
differentiation
Effects
0.000
description
1
230000029087
digestion
Effects
0.000
description
1
108010085933
diguanylate cyclase
Proteins
0.000
description
1
SLPJGDQJLTYWCI-UHFFFAOYSA-N
dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine
Chemical compound
BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br
SLPJGDQJLTYWCI-UHFFFAOYSA-N
0.000
description
1
230000003292
diminished effect
Effects
0.000
description
1
208000016097
disease of metabolism
Diseases
0.000
description
1
208000037765
diseases and disorders
Diseases
0.000
description
1
238000010494
dissociation reaction
Methods
0.000
description
1
230000005593
dissociations
Effects
0.000
description
1
210000004921
distal colon
Anatomy
0.000
description
1
239000002552
dosage form
Substances
0.000
description
1
230000003828
downregulation
Effects
0.000
description
1
239000003937
drug carrier
Substances
0.000
description
1
239000000890
drug combination
Substances
0.000
description
1
238000009510
drug design
Methods
0.000
description
1
238000012912
drug discovery process
Methods
0.000
description
1
238000002651
drug therapy
Methods
0.000
description
1
241001493065
dsRNA viruses
Species
0.000
description
1
238000013399
early diagnosis
Methods
0.000
description
1
230000002526
effect on cardiovascular system
Effects
0.000
description
1
239000000839
emulsion
Substances
0.000
description
1
229940073621
enbrel
Drugs
0.000
description
1
210000003890
endocrine cell
Anatomy
0.000
description
1
230000013931
endocrine signaling
Effects
0.000
description
1
210000001900
endoderm
Anatomy
0.000
description
1
210000002472
endoplasmic reticulum
Anatomy
0.000
description
1
230000008497
endothelial barrier function
Effects
0.000
description
1
238000001976
enzyme digestion
Methods
0.000
description
1
229940125532
enzyme inhibitor
Drugs
0.000
description
1
229940116977
epidermal growth factor
Drugs
0.000
description
1
201000000165
epidural abscess
Diseases
0.000
description
1
230000001667
episodic effect
Effects
0.000
description
1
230000004890
epithelial barrier function
Effects
0.000
description
1
210000000981
epithelium
Anatomy
0.000
description
1
210000003617
erythrocyte membrane
Anatomy
0.000
description
1
235000020774
essential nutrients
Nutrition
0.000
description
1
102000015694
estrogen receptors
Human genes
0.000
description
1
108010038795
estrogen receptors
Proteins
0.000
description
1
125000001495
ethyl group
Chemical group
[H]C([H])([H])C([H])([H])*
0.000
description
1
238000011156
evaluation
Methods
0.000
description
1
230000010429
evolutionary process
Effects
0.000
description
1
230000002964
excitative effect
Effects
0.000
description
1
230000001747
exhibiting effect
Effects
0.000
description
1
102000013165
exonuclease
Human genes
0.000
description
1
239000013613
expression plasmid
Substances
0.000
description
1
229960000301
factor viii
Drugs
0.000
description
1
201000001386
familial hypercholesterolemia
Diseases
0.000
description
1
201000006061
fatal familial insomnia
Diseases
0.000
description
1
201000010255
female reproductive organ cancer
Diseases
0.000
description
1
208000001031
fetal erythroblastosis
Diseases
0.000
description
1
239000000835
fiber
Substances
0.000
description
1
210000002950
fibroblast
Anatomy
0.000
description
1
230000009969
flowable effect
Effects
0.000
description
1
239000012530
fluid
Substances
0.000
description
1
239000007850
fluorescent dye
Substances
0.000
description
1
238000006062
fragmentation reaction
Methods
0.000
description
1
239000003205
fragrance
Substances
0.000
description
1
VZCYOOQTPOCHFL-OWOJBTEDSA-L
fumarate(2-)
Chemical compound
[O-]C(=O)\C=C\C([O-])=O
VZCYOOQTPOCHFL-OWOJBTEDSA-L
0.000
description
1
210000000232
gallbladder
Anatomy
0.000
description
1
210000000609
ganglia
Anatomy
0.000
description
1
102000034356
gene-regulatory proteins
Human genes
0.000
description
1
108091006104
gene-regulatory proteins
Proteins
0.000
description
1
230000009395
genetic defect
Effects
0.000
description
1
230000007614
genetic variation
Effects
0.000
description
1
210000004602
germ cell
Anatomy
0.000
description
1
210000004907
gland
Anatomy
0.000
description
1
239000011521
glass
Substances
0.000
description
1
230000006377
glucose transport
Effects
0.000
description
1
230000004190
glucose uptake
Effects
0.000
description
1
229930195712
glutamate
Natural products
0.000
description
1
229940049906
glutamate
Drugs
0.000
description
1
235000013922
glutamic acid
Nutrition
0.000
description
1
239000004220
glutamic acid
Substances
0.000
description
1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N
glutamine
Natural products
OC(=O)C(N)CCC(N)=O
ZDXPYRJPNDTMRX-UHFFFAOYSA-N
0.000
description
1
108010040856
glutamyl-cysteinyl-alanine
Proteins
0.000
description
1
229960003180
glutathione
Drugs
0.000
description
1
208000019061
glycogen storage disease due to GLUT2 deficiency
Diseases
0.000
description
1
230000034659
glycolysis
Effects
0.000
description
1
VPZXBVLAVMBEQI-UHFFFAOYSA-N
glycyl-DL-alpha-alanine
Natural products
OC(=O)C(C)NC(=O)CN
VPZXBVLAVMBEQI-UHFFFAOYSA-N
0.000
description
1
201000003872
goiter
Diseases
0.000
description
1
PCHJSUWPFVWCPO-UHFFFAOYSA-N
gold
Chemical compound
[Au]
PCHJSUWPFVWCPO-UHFFFAOYSA-N
0.000
description
1
229910052737
gold
Inorganic materials
0.000
description
1
239000010931
gold
Substances
0.000
description
1
239000005090
green fluorescent protein
Substances
0.000
description
1
239000003102
growth factor
Substances
0.000
description
1
238000001631
haemodialysis
Methods
0.000
description
1
230000003394
haemopoietic effect
Effects
0.000
description
1
230000036541
health
Effects
0.000
description
1
208000016354
hearing loss disease
Diseases
0.000
description
1
208000019622
heart disease
Diseases
0.000
description
1
230000000322
hemodialysis
Effects
0.000
description
1
208000009429
hemophilia B
Diseases
0.000
description
1
208000006454
hepatitis
Diseases
0.000
description
1
231100000283
hepatitis
Toxicity
0.000
description
1
208000002672
hepatitis B
Diseases
0.000
description
1
230000002363
herbicidal effect
Effects
0.000
description
1
239000004009
herbicide
Substances
0.000
description
1
208000025581
hereditary breast carcinoma
Diseases
0.000
description
1
102000034345
heterotrimeric G proteins
Human genes
0.000
description
1
108091006093
heterotrimeric G proteins
Proteins
0.000
description
1
101150113423
hisD gene
Proteins
0.000
description
1
230000003284
homeostatic effect
Effects
0.000
description
1
230000003054
hormonal effect
Effects
0.000
description
1
210000005260
human cell
Anatomy
0.000
description
1
230000028996
humoral immune response
Effects
0.000
description
1
229960000890
hydrocortisone
Drugs
0.000
description
1
XMBWDFGMSWQBCA-UHFFFAOYSA-N
hydrogen iodide
Chemical compound
I
XMBWDFGMSWQBCA-UHFFFAOYSA-N
0.000
description
1
125000002887
hydroxy group
Chemical group
[H]O*
0.000
description
1
201000001421
hyperglycemia
Diseases
0.000
description
1
208000033066
hyperinsulinemic hypoglycemia
Diseases
0.000
description
1
230000002102
hyperpolarization
Effects
0.000
description
1
238000003384
imaging method
Methods
0.000
description
1
230000000984
immunochemical effect
Effects
0.000
description
1
230000016784
immunoglobulin production
Effects
0.000
description
1
230000004957
immunoregulator effect
Effects
0.000
description
1
230000001506
immunosuppresive effect
Effects
0.000
description
1
229960003444
immunosuppressant agent
Drugs
0.000
description
1
239000003018
immunosuppressive agent
Substances
0.000
description
1
230000008676
import
Effects
0.000
description
1
230000000415
inactivating effect
Effects
0.000
description
1
230000006698
induction
Effects
0.000
description
1
230000001524
infective effect
Effects
0.000
description
1
208000000509
infertility
Diseases
0.000
description
1
230000036512
infertility
Effects
0.000
description
1
231100000535
infertility
Toxicity
0.000
description
1
230000008595
infiltration
Effects
0.000
description
1
238000001764
infiltration
Methods
0.000
description
1
230000002757
inflammatory effect
Effects
0.000
description
1
230000028709
inflammatory response
Effects
0.000
description
1
229910052500
inorganic mineral
Inorganic materials
0.000
description
1
229910052816
inorganic phosphate
Inorganic materials
0.000
description
1
229960003786
inosine
Drugs
0.000
description
1
206010022437
insomnia
Diseases
0.000
description
1
230000010354
integration
Effects
0.000
description
1
230000031891
intestinal absorption
Effects
0.000
description
1
210000004347
intestinal mucosa
Anatomy
0.000
description
1
238000001361
intraarterial administration
Methods
0.000
description
1
210000005061
intracellular organelle
Anatomy
0.000
description
1
244000000056
intracellular parasite
Species
0.000
description
1
238000007917
intracranial administration
Methods
0.000
description
1
238000007918
intramuscular administration
Methods
0.000
description
1
238000007912
intraperitoneal administration
Methods
0.000
description
1
238000007913
intrathecal administration
Methods
0.000
description
1
238000001990
intravenous administration
Methods
0.000
description
1
238000007914
intraventricular administration
Methods
0.000
description
1
208000030776
invasive breast carcinoma
Diseases
0.000
description
1
238000007852
inverse PCR
Methods
0.000
description
1
229910052742
iron
Inorganic materials
0.000
description
1
208000002551
irritable bowel syndrome
Diseases
0.000
description
1
230000000302
ischemic effect
Effects
0.000
description
1
229960000310
isoleucine
Drugs
0.000
description
1
AGPKZVBTJJNPAG-UHFFFAOYSA-N
isoleucine
Natural products
CCC(C)C(N)C(O)=O
AGPKZVBTJJNPAG-UHFFFAOYSA-N
0.000
description
1
210000003292
kidney cell
Anatomy
0.000
description
1
230000003907
kidney function
Effects
0.000
description
1
206010023497
kuru
Diseases
0.000
description
1
101150066555
lacZ gene
Proteins
0.000
description
1
208000006443
lactic acidosis
Diseases
0.000
description
1
208000003849
large cell carcinoma
Diseases
0.000
description
1
231100000518
lethal
Toxicity
0.000
description
1
230000001665
lethal effect
Effects
0.000
description
1
208000032839
leukemia
Diseases
0.000
description
1
150000002617
leukotrienes
Chemical class
0.000
description
1
229960004194
lidocaine
Drugs
0.000
description
1
230000029226
lipidation
Effects
0.000
description
1
238000001638
lipofection
Methods
0.000
description
1
238000011068
loading method
Methods
0.000
description
1
239000003589
local anesthetic agent
Substances
0.000
description
1
229960005015
local anesthetics
Drugs
0.000
description
1
230000004807
localization
Effects
0.000
description
1
150000004668
long chain fatty acids
Chemical class
0.000
description
1
231100001023
lymphopenia
Toxicity
0.000
description
1
239000006166
lysate
Substances
0.000
description
1
125000003588
lysine group
Chemical group
[H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O
0.000
description
1
210000003712
lysosome
Anatomy
0.000
description
1
230000001868
lysosomic effect
Effects
0.000
description
1
101710130522
mRNA export factor
Proteins
0.000
description
1
230000005291
magnetic effect
Effects
0.000
description
1
230000031852
maintenance of location in cell
Effects
0.000
description
1
230000003211
malignant effect
Effects
0.000
description
1
210000001161
mammalian embryo
Anatomy
0.000
description
1
WPBNNNQJVZRUHP-UHFFFAOYSA-L
manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate
Chemical compound
[Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC
WPBNNNQJVZRUHP-UHFFFAOYSA-L
0.000
description
1
102000043253
matrix Gla protein
Human genes
0.000
description
1
108010057546
matrix Gla protein
Proteins
0.000
description
1
238000005259
measurement
Methods
0.000
description
1
238000002844
melting
Methods
0.000
description
1
230000008018
melting
Effects
0.000
description
1
210000004779
membrane envelope
Anatomy
0.000
description
1
210000003716
mesoderm
Anatomy
0.000
description
1
208000030159
metabolic disease
Diseases
0.000
description
1
230000037323
metabolic rate
Effects
0.000
description
1
230000001394
metastastic effect
Effects
0.000
description
1
MYWUZJCMWCOHBA-VIFPVBQESA-N
methamphetamine
Chemical compound
CN[C@@H](C)CC1=CC=CC=C1
MYWUZJCMWCOHBA-VIFPVBQESA-N
0.000
description
1
229930182817
methionine
Natural products
0.000
description
1
229960000485
methotrexate
Drugs
0.000
description
1
YACKEPLHDIMKIO-UHFFFAOYSA-N
methylphosphonic acid
Chemical class
CP(O)(O)=O
YACKEPLHDIMKIO-UHFFFAOYSA-N
0.000
description
1
229960003404
mexiletine
Drugs
0.000
description
1
244000005700
microbiome
Species
0.000
description
1
239000011859
microparticle
Substances
0.000
description
1
229960003248
mifepristone
Drugs
0.000
description
1
206010027599
migraine
Diseases
0.000
description
1
239000011707
mineral
Substances
0.000
description
1
230000033607
mismatch repair
Effects
0.000
description
1
210000003470
mitochondria
Anatomy
0.000
description
1
210000001700
mitochondrial membrane
Anatomy
0.000
description
1
230000003990
molecular pathway
Effects
0.000
description
1
229910052750
molybdenum
Inorganic materials
0.000
description
1
239000011733
molybdenum
Substances
0.000
description
1
238000012544
monitoring process
Methods
0.000
description
1
210000001616
monocyte
Anatomy
0.000
description
1
230000036651
mood
Effects
0.000
description
1
208000005264
motor neuron disease
Diseases
0.000
description
1
210000003097
mucus
Anatomy
0.000
description
1
238000002887
multiple sequence alignment
Methods
0.000
description
1
201000000585
muscular atrophy
Diseases
0.000
description
1
201000006938
muscular dystrophy
Diseases
0.000
description
1
230000000869
mutational effect
Effects
0.000
description
1
206010028537
myelofibrosis
Diseases
0.000
description
1
201000000050
myeloid neoplasm
Diseases
0.000
description
1
230000002107
myocardial effect
Effects
0.000
description
1
230000002151
myoclonic effect
Effects
0.000
description
1
210000000822
natural killer cell
Anatomy
0.000
description
1
229930014626
natural product
Natural products
0.000
description
1
239000006225
natural substrate
Substances
0.000
description
1
229960004927
neomycin
Drugs
0.000
description
1
210000005170
neoplastic cell
Anatomy
0.000
description
1
210000000653
nervous system
Anatomy
0.000
description
1
210000003061
neural cell
Anatomy
0.000
description
1
230000007372
neural signaling
Effects
0.000
description
1
208000004296
neuralgia
Diseases
0.000
description
1
208000015122
neurodegenerative disease
Diseases
0.000
description
1
230000007472
neurodevelopment
Effects
0.000
description
1
208000018360
neuromuscular disease
Diseases
0.000
description
1
230000003955
neuronal function
Effects
0.000
description
1
230000007996
neuronal plasticity
Effects
0.000
description
1
208000021722
neuropathic pain
Diseases
0.000
description
1
230000003472
neutralizing effect
Effects
0.000
description
1
210000000440
neutrophil
Anatomy
0.000
description
1
229910052759
nickel
Inorganic materials
0.000
description
1
150000002823
nitrates
Chemical class
0.000
description
1
230000024121
nodulation
Effects
0.000
description
1
230000009871
nonspecific binding
Effects
0.000
description
1
231100000956
nontoxicity
Toxicity
0.000
description
1
208000027615
normokalemic periodic paralysis
Diseases
0.000
description
1
230000001473
noxious effect
Effects
0.000
description
1
238000007899
nucleic acid hybridization
Methods
0.000
description
1
239000002777
nucleoside
Substances
0.000
description
1
125000003835
nucleoside group
Chemical group
0.000
description
1
235000015097
nutrients
Nutrition
0.000
description
1
235000020824
obesity
Nutrition
0.000
description
1
208000007064
occipital horn syndrome
Diseases
0.000
description
1
239000003921
oil
Substances
0.000
description
1
239000002751
oligonucleotide probe
Substances
0.000
description
1
229920001542
oligosaccharide
Polymers
0.000
description
1
150000002482
oligosaccharides
Chemical class
0.000
description
1
206010030875
ophthalmoplegia
Diseases
0.000
description
1
150000002891
organic anions
Chemical class
0.000
description
1
150000002892
organic cations
Chemical class
0.000
description
1
239000003960
organic solvent
Substances
0.000
description
1
230000003204
osmotic effect
Effects
0.000
description
1
201000008482
osteoarthritis
Diseases
0.000
description
1
238000012261
overproduction
Methods
0.000
description
1
230000010627
oxidative phosphorylation
Effects
0.000
description
1
229940094443
oxytocics prostaglandins
Drugs
0.000
description
1
230000037324
pain perception
Effects
0.000
description
1
210000000277
pancreatic duct
Anatomy
0.000
description
1
229940014662
pantothenate
Drugs
0.000
description
1
235000019161
pantothenic acid
Nutrition
0.000
description
1
239000011713
pantothenic acid
Substances
0.000
description
1
208000002851
paranoid schizophrenia
Diseases
0.000
description
1
244000045947
parasite
Species
0.000
description
1
230000003071
parasitic effect
Effects
0.000
description
1
230000000849
parathyroid
Effects
0.000
description
1
208000012404
paroxysmal familial ventricular fibrillation
Diseases
0.000
description
1
201000003045
paroxysmal nocturnal hemoglobinuria
Diseases
0.000
description
1
244000052769
pathogen
Species
0.000
description
1
230000001717
pathogenic effect
Effects
0.000
description
1
230000006320
pegylation
Effects
0.000
description
1
230000035515
penetration
Effects
0.000
description
1
210000003899
penis
Anatomy
0.000
description
1
229940111202
pepsin
Drugs
0.000
description
1
108010082406
peptide permease
Proteins
0.000
description
1
238000010647
peptide synthesis reaction
Methods
0.000
description
1
230000008447
perception
Effects
0.000
description
1
230000002093
peripheral effect
Effects
0.000
description
1
210000001428
peripheral nervous system
Anatomy
0.000
description
1
208000027232
peripheral nervous system disease
Diseases
0.000
description
1
208000033808
peripheral neuropathy
Diseases
0.000
description
1
230000035699
permeability
Effects
0.000
description
1
230000000858
peroxisomal effect
Effects
0.000
description
1
230000008782
phagocytosis
Effects
0.000
description
1
239000008194
pharmaceutical composition
Substances
0.000
description
1
239000012071
phase
Substances
0.000
description
1
COLNVLDHVKWLRT-UHFFFAOYSA-N
phenylalanine
Natural products
OC(=O)C(N)CC1=CC=CC=C1
COLNVLDHVKWLRT-UHFFFAOYSA-N
0.000
description
1
BQVCCPGCDUSGOE-UHFFFAOYSA-N
phenylarsine oxide
Chemical compound
O=[As]C1=CC=CC=C1
BQVCCPGCDUSGOE-UHFFFAOYSA-N
0.000
description
1
208000028591
pheochromocytoma
Diseases
0.000
description
1
239000003016
pheromone
Substances
0.000
description
1
NBIIXXVUZAFLBC-UHFFFAOYSA-K
phosphate
Chemical compound
[O-]P([O-])([O-])=O
NBIIXXVUZAFLBC-UHFFFAOYSA-K
0.000
description
1
239000010452
phosphate
Substances
0.000
description
1
150000003904
phospholipids
Chemical class
0.000
description
1
150000008300
phosphoramidites
Chemical class
0.000
description
1
150000003013
phosphoric acid derivatives
Chemical class
0.000
description
1
102000020233
phosphotransferase
Human genes
0.000
description
1
230000002186
photoactivation
Effects
0.000
description
1
230000021715
photosynthesis, light harvesting
Effects
0.000
description
1
230000004962
physiological condition
Effects
0.000
description
1
230000035790
physiological processes and functions
Effects
0.000
description
1
210000002826
placenta
Anatomy
0.000
description
1
230000036470
plasma concentration
Effects
0.000
description
1
229920001983
poloxamer
Polymers
0.000
description
1
238000002264
polyacrylamide gel electrophoresis
Methods
0.000
description
1
229920000447
polyanionic polymer
Polymers
0.000
description
1
208000037244
polycythemia vera
Diseases
0.000
description
1
229920005862
polyol
Polymers
0.000
description
1
150000003077
polyols
Chemical class
0.000
description
1
238000010837
poor prognosis
Methods
0.000
description
1
230000001242
postsynaptic effect
Effects
0.000
description
1
230000001124
posttranscriptional effect
Effects
0.000
description
1
108010083945
potassium channel protein TREK-1
Proteins
0.000
description
1
239000000843
powder
Substances
0.000
description
1
238000001556
precipitation
Methods
0.000
description
1
230000035935
pregnancy
Effects
0.000
description
1
229960000249
pregnenolone
Drugs
0.000
description
1
ORNBQBCIOKFOEO-QGVNFLHTSA-N
pregnenolone
Chemical compound
C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2
ORNBQBCIOKFOEO-QGVNFLHTSA-N
0.000
description
1
238000002953
preparative HPLC
Methods
0.000
description
1
201000009395
primary hyperaldosteronism
Diseases
0.000
description
1
239000000186
progesterone
Substances
0.000
description
1
229960003387
progesterone
Drugs
0.000
description
1
230000000750
progressive effect
Effects
0.000
description
1
201000002212
progressive supranuclear palsy
Diseases
0.000
description
1
210000001236
prokaryotic cell
Anatomy
0.000
description
1
230000001915
proofreading effect
Effects
0.000
description
1
210000002307
prostate
Anatomy
0.000
description
1
208000023958
prostate neoplasm
Diseases
0.000
description
1
230000001681
protective effect
Effects
0.000
description
1
230000004952
protein activity
Effects
0.000
description
1
230000012846
protein folding
Effects
0.000
description
1
230000004853
protein function
Effects
0.000
description
1
230000018883
protein targeting
Effects
0.000
description
1
244000000040
protozoan parasite
Species
0.000
description
1
208000020016
psychiatric disease
Diseases
0.000
description
1
238000011002
quantification
Methods
0.000
description
1
230000006340
racemization
Effects
0.000
description
1
206010061928
radiculitis
Diseases
0.000
description
1
230000002285
radioactive effect
Effects
0.000
description
1
238000000163
radioactive labelling
Methods
0.000
description
1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N
rapamycin
Natural products
COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C
ZAHRKKWIAAJSAO-UHFFFAOYSA-N
0.000
description
1
230000009103
reabsorption
Effects
0.000
description
1
208000002574
reactive arthritis
Diseases
0.000
description
1
238000003753
real-time PCR
Methods
0.000
description
1
108700015048
receptor decoy activity proteins
Proteins
0.000
description
1
230000000306
recurrent effect
Effects
0.000
description
1
230000002829
reductive effect
Effects
0.000
description
1
230000008929
regeneration
Effects
0.000
description
1
238000011069
regeneration method
Methods
0.000
description
1
230000007363
regulatory process
Effects
0.000
description
1
208000014318
renal tubule disease
Diseases
0.000
description
1
230000003362
replicative effect
Effects
0.000
description
1
230000002336
repolarization
Effects
0.000
description
1
239000011347
resin
Substances
0.000
description
1
229920005989
resin
Polymers
0.000
description
1
230000000241
respiratory effect
Effects
0.000
description
1
230000003938
response to stress
Effects
0.000
description
1
108091008146
restriction endonucleases
Proteins
0.000
description
1
210000001995
reticulocyte
Anatomy
0.000
description
1
229960003471
retinol
Drugs
0.000
description
1
235000020944
retinol
Nutrition
0.000
description
1
239000011607
retinol
Substances
0.000
description
1
230000001177
retroviral effect
Effects
0.000
description
1
238000012552
review
Methods
0.000
description
1
206010039083
rhinitis
Diseases
0.000
description
1
230000033764
rhythmic process
Effects
0.000
description
1
210000003705
ribosome
Anatomy
0.000
description
1
210000003079
salivary gland
Anatomy
0.000
description
1
150000003839
salts
Chemical class
0.000
description
1
201000000306
sarcoidosis
Diseases
0.000
description
1
238000013391
scatchard analysis
Methods
0.000
description
1
238000005204
segregation
Methods
0.000
description
1
238000010187
selection method
Methods
0.000
description
1
239000006152
selective media
Substances
0.000
description
1
229910052711
selenium
Inorganic materials
0.000
description
1
239000011669
selenium
Substances
0.000
description
1
230000008786
sensory perception of smell
Effects
0.000
description
1
238000000926
separation method
Methods
0.000
description
1
230000000405
serological effect
Effects
0.000
description
1
229940076279
serotonin
Drugs
0.000
description
1
208000002491
severe combined immunodeficiency
Diseases
0.000
description
1
208000007056
sickle cell anemia
Diseases
0.000
description
1
230000003584
silencer
Effects
0.000
description
1
229960002930
sirolimus
Drugs
0.000
description
1
QFJCIRLUMZQUOT-HPLJOQBZSA-N
sirolimus
Chemical compound
C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1
QFJCIRLUMZQUOT-HPLJOQBZSA-N
0.000
description
1
238000002741
site-directed mutagenesis
Methods
0.000
description
1
210000003491
skin
Anatomy
0.000
description
1
239000004055
small Interfering RNA
Substances
0.000
description
1
230000016160
smooth muscle contraction
Effects
0.000
description
1
230000000392
somatic effect
Effects
0.000
description
1
230000037439
somatic mutation
Effects
0.000
description
1
210000000952
spleen
Anatomy
0.000
description
1
206010041823
squamous cell carcinoma
Diseases
0.000
description
1
230000006641
stabilisation
Effects
0.000
description
1
238000011105
stabilization
Methods
0.000
description
1
239000003381
stabilizer
Substances
0.000
description
1
230000010473
stable expression
Effects
0.000
description
1
238000010561
standard procedure
Methods
0.000
description
1
235000019698
starch
Nutrition
0.000
description
1
150000003431
steroids
Chemical class
0.000
description
1
150000003432
sterols
Chemical class
0.000
description
1
235000003702
sterols
Nutrition
0.000
description
1
238000007920
subcutaneous administration
Methods
0.000
description
1
KDYFGRWQOYBRFD-UHFFFAOYSA-L
succinate(2-)
Chemical compound
[O-]C(=O)CCC([O-])=O
KDYFGRWQOYBRFD-UHFFFAOYSA-L
0.000
description
1
125000000446
sulfanediyl group
Chemical group
*S*
0.000
description
1
239000006228
supernatant
Substances
0.000
description
1
230000001629
suppression
Effects
0.000
description
1
238000001356
surgical procedure
Methods
0.000
description
1
210000000225
synapse
Anatomy
0.000
description
1
230000000946
synaptic effect
Effects
0.000
description
1
230000002194
synthesizing effect
Effects
0.000
description
1
230000009897
systematic effect
Effects
0.000
description
1
230000009885
systemic effect
Effects
0.000
description
1
201000000596
systemic lupus erythematosus
Diseases
0.000
description
1
230000028016
temperature homeostasis
Effects
0.000
description
1
208000001608
teratocarcinoma
Diseases
0.000
description
1
210000001550
testis
Anatomy
0.000
description
1
229960002180
tetracycline
Drugs
0.000
description
1
229930101283
tetracycline
Natural products
0.000
description
1
235000019364
tetracycline
Nutrition
0.000
description
1
150000003522
tetracyclines
Chemical class
0.000
description
1
231100001274
therapeutic index
Toxicity
0.000
description
1
RYYWUUFWQRZTIU-UHFFFAOYSA-K
thiophosphate
Chemical compound
[O-]P([O-])([O-])=S
RYYWUUFWQRZTIU-UHFFFAOYSA-K
0.000
description
1
201000005060
thrombophlebitis
Diseases
0.000
description
1
210000001541
thymus gland
Anatomy
0.000
description
1
229960002175
thyroglobulin
Drugs
0.000
description
1
238000012090
tissue culture technique
Methods
0.000
description
1
230000000699
topical effect
Effects
0.000
description
1
231100000167
toxic agent
Toxicity
0.000
description
1
239000003440
toxic substance
Substances
0.000
description
1
231100000027
toxicology
Toxicity
0.000
description
1
239000003053
toxin
Substances
0.000
description
1
231100000765
toxin
Toxicity
0.000
description
1
108700012359
toxins
Proteins
0.000
description
1
VZCYOOQTPOCHFL-UHFFFAOYSA-N
trans-butenedioic acid
Natural products
OC(=O)C=CC(O)=O
VZCYOOQTPOCHFL-UHFFFAOYSA-N
0.000
description
1
108091008023
transcriptional regulators
Proteins
0.000
description
1
230000002463
transducing effect
Effects
0.000
description
1
230000018889
transepithelial transport
Effects
0.000
description
1
238000003151
transfection method
Methods
0.000
description
1
230000007704
transition
Effects
0.000
description
1
230000005945
translocation
Effects
0.000
description
1
238000002054
transplantation
Methods
0.000
description
1
QORWJWZARLRLPR-UHFFFAOYSA-H
tricalcium bis(phosphate)
Chemical compound
[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O
QORWJWZARLRLPR-UHFFFAOYSA-H
0.000
description
1
208000020049
trigeminal nerve disease
Diseases
0.000
description
1
101150081616
trpB gene
Proteins
0.000
description
1
101150111232
trpB-1 gene
Proteins
0.000
description
1
208000009999
tuberous sclerosis
Diseases
0.000
description
1
230000010245
tubular reabsorption
Effects
0.000
description
1
210000004881
tumor cell
Anatomy
0.000
description
1
230000005740
tumor formation
Effects
0.000
description
1
230000004614
tumor growth
Effects
0.000
description
1
208000001072
type 2 diabetes mellitus
Diseases
0.000
description
1
230000005951
type IV hypersensitivity
Effects
0.000
description
1
208000027930
type IV hypersensitivity disease
Diseases
0.000
description
1
OUYCCCASQSFEME-UHFFFAOYSA-N
tyrosine
Natural products
OC(=O)C(N)CC1=CC=C(O)C=C1
OUYCCCASQSFEME-UHFFFAOYSA-N
0.000
description
1
241000701447
unidentified baculovirus
Species
0.000
description
1
210000003932
urinary bladder
Anatomy
0.000
description
1
210000004291
uterus
Anatomy
0.000
description
1
239000004474
valine
Substances
0.000
description
1
230000003639
vasoconstrictive effect
Effects
0.000
description
1
230000001457
vasomotor
Effects
0.000
description
1
230000009385
viral infection
Effects
0.000
description
1
201000010044
viral meningitis
Diseases
0.000
description
1
230000002747
voluntary effect
Effects
0.000
description
1
235000012431
wafers
Nutrition
0.000
description
1
239000002699
waste material
Substances
0.000
description
1
238000001262
western blot
Methods
0.000
description
1
QAOHCFGKCWTBGC-UHFFFAOYSA-N
wybutosine
Natural products
C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O
QAOHCFGKCWTBGC-UHFFFAOYSA-N
0.000
description
1
QAOHCFGKCWTBGC-QHOAOGIMSA-N
wybutosine
Chemical compound
C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
QAOHCFGKCWTBGC-QHOAOGIMSA-N
0.000
description
1
229910052725
zinc
Inorganic materials
0.000
description
1
239000011701
zinc
Substances
0.000
description
1
Classifications
C —CHEMISTRY; METALLURGY
C07 —ORGANIC CHEMISTRY
C07K —PEPTIDES
C07K14/00 —Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K14/435 —Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
C07K14/705 —Receptors; Cell surface antigens; Cell surface determinants
A —HUMAN NECESSITIES
A01 —AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
A01K —ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
A01K2217/00 —Genetically modified animals
A01K2217/05 —Animals comprising random inserted nucleic acids (transgenic)
A —HUMAN NECESSITIES
A61 —MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K —PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00 —Medicinal preparations containing peptides
Definitions
the invention
relates to novel nucleic acids, transporters and ion channels encoded by these nucleic acids, and to the use of these nucleic acids and proteins in the diagnosis, treatment, and prevention of transport, neurological, muscle, immunological and cell proliferative disorders.
the invention
also relates to the assessment of the effects of exogenous compounds on the expression of nucleic acids and transporters and ion channels.
Eukaryotic cells
are surrounded and subdivided into functionally distinct organelles by hydrophobic lipid bilayer membranes which are highly impermeable to most polar molecules.
Cells and organelles
require transport proteins to import and export essential nutrients and metal ions including K + , NH 4 + , P réelle SO 4 2" , sugars, and vitamins, as well as various metabolic waste products.
Transport proteins
also play roles in antibiotic resistance, toxin secretion, ion balance, synaptic neurotransmission, kidney function, intestinal absorption, tumor growth, and other diverse cell functions (Griffith, J. and C. Sansom (1998) The Transporter Facts Book. Academic Press, San Diego CA, pp. 3-29).
Transport
can occur by a passive concentration-dependent mechanism, or can be linked to an energy source such as ATP hydrolysis or an ion gradient.
Proteins that function in transport
include carrier proteins, which bind to a specific solute and undergo a conformational change that translocates the bound solute across the membrane, and channel proteins, which form hydrophilic pores that allow specific solutes to diffuse through the membrane down an electrochemical solute gradient.
Carrier proteins which transport a single solute from one side of the membrane to the other
are called uniporters.
coupled transporters
link the transfer of one solute with simultaneous or sequential transfer of a second solute, either in the same direction (symport) or in the opposite direction (antiport).
intestinal and kidney epithelium
contains a variety of symporter systems driven by the sodium gradient that exists across the plasma membrane. Sodium moves into the cell down its electrochemical gradient and brings the solute into the cell with it. The sodium gradient that provides the driving force for solute uptake is maintained by the ubiquitous Na7K + ATPase system.
Sodium-coupled transporters
include the mammalian glucose transporter (SGLT1), iodide transporter (NIS), and multivitamin transporter (SMVT). All three transporters have twelve putative transmembrane segments, extracellular glycosylation sites, and cytoplasmically- oriented N- and C-termini. NIS plays a crucial role in the evaluation, diagnosis, and treatment of various thyroid pathologies because it is the molecular basis for radioiodide thyroid-imaging techniques and for specific targeting of radioisotopes to the thyroid gland (Levy, O. et al. (1997) Proc. Natl. Acad. Sci. USA 94:5568-5573).
SMVT
is expressed in the intestinal mucosa, kidney, and placenta, and is implicated in the transport of the water-soluble vitamins, e.g., biotin and pantothenate (Prasad, P.D. et al. (1998) J. Biol. Chem. 273:7501-7506).
MFS
major facilitator superfamily
MFS transporters
are single polypeptide carriers that transport small solutes in response to ion gradients.
MFS transporters
found in all classes of living organisms, and include transporters for sugars, oligosaccharides, phosphates, nitrates, nucleosides, monocarboxylates, and drugs.
MFS transporters found in eukaryotes
all have a structure comprising 12 transmembrane segments (Pao, S.S. et al. (1998) Microbiol. Molec. Biol. Rev. 62: 1-34).
the largest family of MFS transporters
is the sugar transporter family, which includes the seven glucose transporters (GLUT1-GLUT7) found in humans that are required for the transport of glucose and other hexose sugars. These glucose transport proteins have unique tissue distributions and physiological functions.
GLUT1
provides many cell types with their basal glucose requirements and transports glucose across epithelial and endothelial barrier tissues; GLUT2 facilitates glucose uptake or efflux from the liver; GLUT3 regulates glucose supply to neurons; GLUT4 is responsible for insulin- regulated glucose disposal; and GLUT5 regulates fructose uptake into skeletal muscle. Defects in glucose transporters are involved in a recently identified neurological syndrome causing infantile seizures and developmental delay, as well as glycogen storage disease, Fanconi-Bickel syndrome, and non-insulin-dependent diabetes mellitus (Mueckler, M. (1994) Eur. J. Biochem. 219:713-725; Longo, N. and L.J. Elsas (1998) Adv. Pediatr. 45:293-313).
Monocarboxylate anion transporters
are proton-coupled symporters with a broad substrate specificity that includes L-lactate, pyruvate, and the ketone bodies acetate, acetoacetate, and beta-hydroxybutyrate. At least seven isoforms have been identified to date. The isoforms are predicted to have twelve transmembrane (TM) helical domains with a large intracellular loop between TM6 and TM7, and play a critical role in maintaining intracellular pH by removing the protons that are produced stoichiometrically with lactate during glycolysis.
TM
transmembrane
H + -monocarboxylate transporter
is that of the erythrocyte membrane, which transports L-lactate and a wide range of other aliphatic monocarboxylates.
Other cells
possess H + -linked monocarboxylate transporters with differing substrate and inhibitor selectivities.
cardiac muscle and tumor cells
have transporters that differ in their K m values for certain substrates, including stereoselectivity for L- over D-lactate, and in their sensitivity to inhibitors.
Organic anion transporters
are selective for hydrophobic, charged molecules with electron-attracting side groups.
Organic cation transporters
such as the ammonium transporter, mediate the secretion of a variety of drugs and endogenous metabolites, and contribute to the maintenance of intercellular pH (Poole, R.C. and A.P. Halestrap (1993) Am. J. Physiol. 264:C761-C782; Price, N.T. et al. (1998) Biochem. J. 329:321-328; and Martinelle, K. and I. Haggstrom (1993) J. Biotechnol. 30:339-350).
ATP-binding cassette (ABC) transporters
are members of a superfamily of membrane proteins that transport substances ranging from small molecules such as ions, sugars, amino acids, peptides, and phospholipids, to lipopeptides, large proteins, and complex hydrophobic drugs.
ABC transporters
consist of four modules: two nucleotide-binding domains (NBD), which hydrolyze ATP to supply the energy required for transport, and two membrane-spanning domains (MSD), each containing six putative transmembrane segments.
NBD
nucleotide-binding domains
MSD
membrane-spanning domains
These four modules
may be encoded by a single gene, as is the case for the cystic fibrosis transmembrane regulator (CFTR), or by separate genes. When encoded by separate genes, each gene product contains a single NBD and MSD.
CFTR
cystic fibrosis
ALDP
adrenoleukodystrophy protein
PMP70
peroxisomal membrane protein-70, PMP70
SUR
hyperinsulinemic hypoglycemia
MDR
multidrug resistance
a number of metal ions
such as iron, zinc, copper, cobalt, manganese, molybdenum, selenium, nickel, and chromium are important as cofactors for a number of enzymes.
copper
is involved in hemoglobin synthesis, connective tissue metabolism, and bone development, by acting as a cofactor in oxidoreductases such as superoxide dismutase, ferroxidase (ceruloplasmin), and lysyl oxidase.
Copper and other metal ions
must be provided in the diet, and are absorbed by transporters in the gastrointestinal tract. Plasma proteins transport the metal ions to the liver and other target organs, where specific transporters move the ions into cells and cellular organelles as needed. Imbalances in metal ion metabolism have been associated with a number of disease states (Danks, D.M. (1986) J. Med. Genet. 23:99-106).
Fatty acid transport protein
an integral membrane protein with four transmembrane segments, is expressed in tissues exhibiting high levels of plasma membrane fatty acid flux, such as muscle, heart, and adipose. Expression of FATP is upregulated in 3T3-L1 cells during adipose conversion, and expression in COS7 fibroblasts elevates uptake of long-chain fatty acids (Hui, T.Y. et al. (1998) J. Biol. Chem. 273:27420-27429).
the lipocalin superfamily
constitutes a phylogenetically conserved group of more than forty proteins that function as extracellular ligand-binding proteins which bind and transport small hydrophobic molecules. Members of this family function as carriers of retinoids, odorants, chromophores, pheromones, allergens, and sterols, and in a variety of processes including nutrient transport, cell growth regulation, immune response, and prostaglandin synthesis. A subset of these proteins may be multifunctional, serving as either a biosynthetic enzyme or as a specific enzyme inhibitor. (Tanaka, T. et al. (1997) J. Biol. Chem. 272:15789-15795; and van't Hof, W. et al. (1997) J. Biol. Chem. 272:1837-1841.)
Lipocalins
Members of the lipocalin family display unusually low levels of overall sequence conservation. Pairwise sequence identity often falls below 20%. Sequence similarity between family members is limited to conserved cysteines which form disulfide bonds and three motifs which form a juxtaposed cluster that functions as a target cell recognition site.
the lipocalins
share an eight stranded, anti- parallel beta-sheet which folds back on itself to form a continuously hydrogen-bonded beta-barrel.
the pocket formed by the barrel
functions as an internal ligand binding site. Seven loops (LI to L7) form short beta-hairpins, except loop LI which is a large omega loop that forms a lid to partially close the internal ligand-binding site (Flower (1996) Biochem. J. 318: 1-14).
Lipocalins
are important transport molecules. Each lipocalin associates with a particular ligand and delivers that ligand to appropriate target sites within the organism.
Retinol-binding protein
(RBP), one of the best characterized lipocalins, transports retinol from stores within the liver to target tissues.
Apolipoprotein D
(apo D), a component of high density lipoproteins (HDLs) and low density lipoproteins (LDLs), functions in the targeted collection and delivery of cholesterol throughout the body. Lipocalins are also involved in cell regulatory processes.
Apo D
which is identical to gross- cystic-disease-fluid protein (GCDFP)-24, is a progesterone/pregnenolone-binding protein expressed at high levels in breast cyst fluid. Secretion of apo D in certain human breast cancer cell lines is accompanied by reduced cell proliferation and progression of cells to a more differentiated phenotype. Similarly, apo D and another lipocalin, ⁇ ,-acid glycoprotein (AGP), are involved in nerve cell regeneration. AGP is also involved in anti-inflammatory and immunosuppressive activities. AGP is one of the positive acute-phase proteins (APP); circulating levels of AGP increase in response to stress and inflammatory stimulation.
APP
positive acute-phase proteins
AGP
accumulates at sites of inflammation where it inhibits platelet and neutrophil activation and inhibits phagocytosis.
the immunomodulatory properties of AGP
are due to glycosylation.
AGP
is 40% carbohydrate, making it unusually acidic and soluble.
the glycosylation pattern of AGP
changes during acute-phase response, and deglycosylated AGP has no immunosuppressive activity (Flower (1994) FEBS Lett. 354:7-11; Flower (1996) supra).
the lipocalin superfamily
also includes several animal allergens, including the mouse major urinary protein (mMUP), the rat ⁇ -2-microgloobulin (rA2U), the bovine ⁇ -lactoglobulin ( ⁇ lg), the cockroach allergen (Bla g4), bovine dander allergen (Bos d2), and the major horse allergen, designated Equus caballus allergen 1 (Equ cl).
Equ cl
is a powerful allergen responsible for about 80% of anti- horse IgE antibody response in patients who are chronically exposed to horse allergens. It appears that lipocalins may contain a common structure that is able to induce the IgE response (Gregoire, C. et al., (1996) J. Biol. Chem. 271 :32951-32959).
Lipocalins
are used as diagnostic and prognostic markers in a variety of disease states.
the plasma level of AGP
is monitored during pregnancy and in diagnosis and prognosis of conditions including cancer chemotherapy, renal disfunction, myocardial infarction, arthritis, and multiple sclerosis.
RBP
is used clinically as a marker of tubular reabsorption in the kidney
apo D
is a marker in gross cystic breast disease (Flower (1996) supra).
the use of lipocalin animal allergens
may help in the diagnosis of allergic reactions to horses (Gregoire supra), pigs, cockroaches, mice and rats.
Mitochondrial carrier proteins
are transmembrane-spanning proteins which transport ions and charged metabolites between the cytosol and the mitochondrial matrix. Examples include the ADP, ATP carrier protein; the 2-oxoglutarate/malate carrier; the phosphate carrier protein; the pyruvate carrier; the dicarboxylate carrier which transports malate, succinate, fumarate, and phosphate; the tricarboxylate carrier which transports citrate and malate; and the Grave's disease carrier protein, a protein recognized by IgG in patients with active Grave's disease, an autoimmune disorder resulting in hyperthyroidism.
Proteins in this family
consist of three tandem repeats of an approximately 100 amino acid domain, each of which contains two transmembrane regions (Stryer, L. (1995) Biochemistry, W.H. Freeman and Company, New York NY, p. 551; PROSITE PDOC00189 Mitochondrial energy transfer proteins signature; Online Mendelian Inheritance in Man (OMIM) *275000 Graves Disease).
This class of transporters
also includes the mitochondrial uncoupling proteins, which create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis. The result is energy dissipation in the form of heat.
Mitochondrial uncoupling proteins